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CHAPTER I 
INTRODUCTION 
Conventional dosage form is very popular because of ease of self 
administration, compact in nature, easy to manufacture and it can be delivered in 
accurate dose. Some drugs having poor bioavailability are with poor aqueous 
solubility and or slow dissolution rate in the biological fluids. Poorly water-soluble 
compounds with dissolution rate limited and results low oral bioavailability. 
Solubility is the major challenges in pharmaceutical formulation, all drugs must 
possess some degree of aqueous solubility, and most drugs should be lipophilic to 
permeate the biological membranes via passive diffusion. The water solubility of any 
drug is determined by its potency and its type of formulation. For pharmacological 
response to be shown the solubility is one of the important parameter to achieve 
desired concentration of drug in systemic circulation. Poorly water-soluble drug 
candidates often emerge from contemporary drug discovery programs, and present 
formulators with considerable technical challenges (Chaudhary V.B and Patel, 2013). 
Solubility enhancement of various poorly soluble compounds is a challenging 
task for researchers and pharmaceutical scientists. Solubility is one of the important 
parameter to achieve desired concentration of drug in systemic circulation for 
pharmacological response.  
  There are many techniques which are used to enhance the aqueous solubility. 
The ability to increase aqueous solubility can thus be a valuable aid to increase 
efficiency and/or reduce side effects for certain drugs. This is true for parenterally, 
topically and orally administered solutions. The pharmacopoeia lists solubility in 
terms of dissolve 1g of solute, if exact solubility is not known; the pharmacopoeia 
provides general terms to describe a given range.  
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Table a: Expression for approximate solubility definition in USP 
Solubility 
definition 
Parts solvent 
required 
for one part of solute 
Solubility 
range 
(mg / ml) 
Solubility assigned 
(mg /ml) 
Very soluble Less than 1 >1000 1000 
Freely soluble From 1-10 100-1000 100 
Soluble From   10-30 33-100 33 
Sparingly soluble From 30-100 10-33 10 
Slightly soluble From 100-1000 1-10 1 
Very slightly 
soluble 
From 1000-10,000 0.1-1 0.1 
Insoluble or 
practically insoluble 
 
More than 10,000 
 
<0.1 
 
0.01 
 
General parameters affecting solubility are particle size, shape and surface 
area physicochemical properties of drugs, and physical forms of drugs, solvents, pH 
of the medium, temperature and use of surfactants. 
Needs of solubility  
Therapeutic effectiveness of a drug depends upon the bioavailability and 
ultimately upon the solubility of drug molecules. Solubility is one of the important 
parameter to achieve desired concentration of drug in systemic circulation for 
pharmacological response. 
Due to advanced research & development, there are varieties of new drugs & 
their derivatives are available. But more than 40% of lipophilic drug candidates fail to 
reach market due to poor bioavailability, even though these drugs might exhibit 
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potential pharmacodynamic activities. The lipophilic drug that reaches market 
requires a high dose to attain proper pharmacological action. The basic aim of the 
further formulation & development section is to make that drug available at proper 
site of action within optimum dose. (Chaudhary V.B and Patel, 2013) 
 
MECHANISM OF SOLUBILITY 
The term „solubility‟ is defined as maximum amount of solute that can be 
dissolved in a given amount of solvent. It can also be defined quantitatively as well as 
qualitatively. Quantitatively it is defined as the concentration of the solute in a 
saturated solution at may be defined as the spontaneous interaction of two or more 
substances to form a homogenous molecular dispersion. A saturated solution is one in 
which the solute is in equilibrium with the solvent. 
Step 1        Step2         Step 3  
             
Holes open in the  Molecules of the solid breaks  The freed solid molecule  
solvent   away is integrated into the 
                                hole in the solvent    
   
Methods of Solubility Enhancement:  
Classical and highly employed approaches to enhance the aqueous solubility 
and thus the bioavailability of poorly soluble drugs especially, BCS Class II drugs 
involve the solubilization by application of principles like pH adjustment, cosolvency, 
microemulsification, selfemulsification,micelles, liposomes and emulsions. Each 
method is dealing with some merits and demerits. Hence the decision of the method is 
a crucial step in the formulation process. (Daisy Sharma et al, 2009) 
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Salt formation: 
Salt formation of poorly soluble drug candidates (weak acids and bases) has 
been a strategy for several decades to enhance solubility. It is an effective method in 
parenteral and other liquid formulations, as well as in solid dosage forms. 
Approximately 300 new chemical entities approved by the FDA during the 12 years 
from1995 to 2006 for marketing, 120 were in salt forms. In addition, out of the 101 
approved salts of basic drugs, 54 salts were prepared with hydrochloric acid, 
indicating the hydrochloride was the predominant salt form. The aqueous solubility of 
an acidic or basic drug as a function of pH dictates whether the compound will form 
suitable salts. The pH-solubility interrelationships also dictate what counter ions 
would be necessary to form salts, how easily the salts may dissociate into their free 
acid or base forms, what their dissolution behavior would be under different GI pH 
conditions, and whether solubility and dissolution rate of salts would be influenced by 
common ion. Several reviews have outlined general strategies and considerations for 
salt selection. For the salt formation drug should have ionizable groups that will assist 
salt formation. The criteria used to select counter ion is as follows:  
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 There should be minimum difference of 2-3 pKa units between the drug and 
the counter ion.  
 Counter ion should decrease crystal lattice forces.  
 It should be FDA approved or should have enough toxicological data to 
support the 
 Selection of the counter ion.  
This technique has tremendous capability to enhance dissolution rate but it is 
grasped with disadvantages like approval of salts is a tedious task and also not useful 
for neutral molecules. 
 
Polymeric Alteration:  
Different crystalline forms of a drug that may have different properties are 
known as Polymorphs. Polymorphs may differ in physicochemical properties such as 
physical and chemical stability, shelf-life, melting point, vapor pressure, intrinsic 
solubility, dissolution rate, morphology, density and biological activities as well as 
bioavailability. 
Amongst the stable, unstable and metastable crystalline polymorphs, 
metastable forms are associated with higher energy with increased surface area, 
subsequently solubility, bioavailability and efficacy. With regard to bioavailability, it 
is preferable to change drug from crystal forms into metastable or amorphous forms. 
However, the possibility of a conversion of the high energy amorphous or metastable 
polymorph into a low energy crystal form having low solubility cannot be ruled out 
during manufacture and storage. It is preferable to develop the most 
thermodynamically stable polymorph of the drug to assure reproducible 
bioavailability of the product over its shelf-life under a variety of real-world storage 
conditions. 
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Particle Size Reduction:  
Micronization or nanonization is one of the most potential approaches to 
improve the bioavailability of lipophilic drugs by an increase in surface area and 
saturation solubility by means of reduction of the particle size to sub-micron level. 
Particle size is a critical parameter which should be strictly controlled during the 
preformulation studies of any formulation. Although the reduction in the particle size 
is a successful way to enhance the solubility, if uncontrolled and un-optimized, it can 
lead to re crystallization and re-aggregation of drug on storage. Hence a thorough 
study on particle size and physical stability should be done. Size reduction to 
submicron range is not possible by the conventional milling techniques. Patented 
engineering processes have come up based on the principles of pearl milling high-
pressure homogenization, solution enhanced dispersion by supercritical fluids 
(SEDS), rapid expansion supercritical to aqueous solution (RESAS), spray freezing 
into liquid (SFL) and evaporative precipitation into aqueous solution (EPAS). 
 
SOLID DISPERSIONS 
Solid dispersions represent a useful pharmaceutical technique for increasing 
the dissolution, absorption and therapeutic efficacy of drugs in dosage forms. The 
term solid dispersion refers to the dispersion of one or more active ingredients in an 
inert carrier or matrix at solid state prepared by the melting (fusion), solvent, or 
melting-solvent method. 
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CLASSIFICATION 
I. BASED ON CARRIERS USED: 
a) First generation 
  First generation solid dispersions were prepared using crystalline carriers 
such as urea and sugar, which were the first carriers to be employed in solid 
dispersion. They have the disadvantage of forming crystalline solid dispersion, which 
were thermodynamically more stable and did not release the drug as quickly as 
amorphous ones. 
 
b) Second generation 
Second generation solid dispersions include amorphous carriers instead of 
crystalline carriers which are usually polymers. These polymers include synthetic 
polymers such as povidone (PVP), polyethyleneglycols (PEG) and polymethacrylates 
as well as natural product based polymers such as hydroxylpropylmethyl-cellulose 
(HPMC), ethyl cellulose, and hydroxypropoylcellulose or starch derivates like 
cyclodextrins. 
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c) Third generation 
Recently, it has been shown that the dissolution profile can be improved if the 
carrier has surface activity or self emulsifying properties. Therefore, third generation 
solid dispersions appeared. The use of surfactant such as inulin, inutec SP1, compritol 
888 ATO, gelucire 44/14 and poloxamer 407 as carriers was shown to be effective in 
originating high polymorphic purity and enhanced in vivo bioavailability. 
 
II. THE BASIS OF SOLID STATE STRUCTURE (Bhawana Kapoor et al., 
2012) 
 
1) Drug and polymer exhibiting immiscibility in fluid state 
If a drug and polymer are immiscible in their fluid state, it is expected that 
they would not exhibit miscibility on solidification of the fluid mixture. Such systems 
may be regarded as similar to their corresponding physical mixtures and any 
enhancement in dissolution performance may be owing to modification in 
morphology of drug and/or polymer due to physical transformation solid to liquid 
state and back), intimate drug–polymer mixing, and/or enhanced surface area. 
CHAPTER I                                                                                      INTRODUCTION 
 
Ormeloxifene FDT Reg. No: 261211307 Page 9 
 
Formation of crystalline or amorphous solid dispersions can be biased by the rate of 
solidification of mixture and the rate of crystallization of drug and/or polymer. 
 
2) Drug and polymer exhibiting miscibility in fluid state 
If the drug and polymer are miscible in their fluid state, then the mixture may 
or may not undergo phase separation during solidification, thereby influencing the 
structure of solid dispersion. 
 
a)  Eutectic Mixtures 
Eutectic mixtures are formed when the drug and polymer are miscible in their 
molten state, but on cooling, they crystallize as two distinct components with 
negligible miscibility. When a drug (A) and a carrier (B) are co-melted at their 
eutectic composition defined by point „e‟, as shown schematically in the figure below, 
the melting point of the mixture is lower than the melting point of either drug or 
carrier alone. At the eutectic composition (e), both drug and carrier exist in finely 
divided state, which results in higher surface area and enhanced dissolution rate of 
drug.  
 
FIGURE: (a) Phase diagram of a eutectic mixture (Bhawana Kapoor et al., 2012) 
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b) Crystalline Solid Dispersion 
A crystalline solid dispersion (or suspension) is formed when the rate at which 
drug crystallizes from drug–polymer miscible mixture is greater than the rate at which 
drug–polymer fluid mixture solidifies. 
 
c) Amorphous Solid Dispersion 
If the drug–polymer fluid mixture is cooled at a rate that does not allow for 
drug crystallization, then drug is kinetically trapped in its amorphous or a “solidified-
liquid” state. These types of dispersions have the risk of potential for conversion to a 
more stable and less soluble crystalline form. 
 
f) Solid Solution 
Solid solution is a solid dispersion that is miscible in its fluid as well as solid 
state. These solid solutions may be either of amorphous or crystalline type. In 
amorphous solid solutions as the drug is molecularly dispersed in the carrier matrix, 
its effective surface area is significantly higher and hence the dissolution rate is 
increased. Amorphous solid solutions have improved physical stability of amorphous 
drugs by inhibiting drug crystallization by minimizing molecular mobility. Crystalline 
solid solution may result when a crystalline drug is trapped within a crystalline 
polymeric carrier.  According to extent of miscibility of the two components, solid 
solutions are continuous or discontinuous type. In continuous solid solutions, the two 
components are miscible in the solid state in all proportions. The components that are 
immiscible at intermediate composition, but miscible at extremes of composition are 
referred to as discontinuous solid solutions.   
 
According to the criterion of molecular size of the two components, the solid 
solutions are classified as substitutional and interstitial. In the substitutional solid 
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solution, the solute molecule substitutes for the solvent molecule in the crystal lattice.  
Molecular size of the two components should not differ by more than 15%. An 
interstitial solid solution is obtained when the solute (guest) molecule occupies the 
interstitial space in the solvent (host) lattice. For this to occur, the solute molecule 
diameter should be less than 0.59 than that of solvent molecule.   Therefore, the 
volume of the solute molecule(s) should be less than 20% of the solvent molecule(s). 
Examples include solid solutions of digitoxin, methyltestosterone, predinsolone 
acetate and hydrocortisone acetate in the matrix of PEG 6000. They all exhibit faster 
rate of dissolution. 
 
 
FIGURE-(b):  Schematic representation of sub stituitional solid solution and 
interstitial solid solution  
DIFFERENT METHODS OF PREPARATION OF SOLID DISPERSION 
Several approaches have been attempted for the preparation of solid 
dispersion, to improve the solubility and dissolution characteristics of poorly water-
soluble drugs which include (Ahuja Nitika, et al., 2012) 
1) Spray drying 
2) Fusion method 
3) Solvent evaporation 
4) Hot-melt extrusion 
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5) Particle size reduction 
6) Supercritical fluid (SCF) processes. 
7) Kneading 
8) Inclusion Complexes 
9) Direct Capsule filling 
10) Electrostatic Spinning Method 
11) Surface-active Carriers 
12) Melt agglomeration  
 
(1) Spray drying 
In this method drug & carrier is dissolved in a volatile organic solvent with 
help of magnetic stirrer to get a clear solution and solvent is evaporated at 400C under 
reduced pressure by using vacuum evaporator, obtained mass is dried in a desiccators 
over anhydrous calcium chloride for 1-2 days depending on the removal rate of 
solvent. The product is crushed, pulverized & sieved through a suitable mesh number 
sieve. 
 
 
Figure (c): Schematic representation of spray drying technique (Ahuja Nitika et al., 
2012) 
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(2) Fusion method 
The fusion process is technically the less difficult method of preparing 
dispersions provided the drug and carrier are miscible in the molten state. This 
process employs melting of the mixture of the drug and carrier in metallic vessel 
heated in an oil bath, immediately after fusion, the sample are poured onto a metallic 
plate which is kept at ice bath.  
 
 (3) Solvent Removal Process 
In this method drug & carrier is dissolved in a volatile organic solvent with 
help of magnetic stirrer to get a clear solution and solvent is removed at room 
temperature, obtained mass is dried in a desiccator over anhydrous calcium chloride 
for 1-2 days depending on the removal rate of solvent at room temperature. The 
product is crushed, pulverized & sieved through a suitable mesh number sieve. 
 
(4) Hot-Melt Extrusion 
The extruder consists of a hoper, barrel, a die, a kneading screw and heaters. 
The physical mixture is introduced into the hopper that is forwarded by feed screw 
and finally is extruded from the die. The effect of screw revolution speed and water 
content on the preparation of SD(s) should be investigated, since these parameters 
have profound impact on the quality of SD(s). In addition, high screw speed –high 
feed rate processes in comparison with low screw speed–low feed rate processes 
caused an increase in extrudate radius and porosity and decrease in mechanical 
strength and drug release rate from the matrix attributed to the expansion promoted 
under certain extrusion conditions. 
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FIGURE-(d):    Single screw melt extruder (Bhawana Kapoor et al., 2012) 
(5) Particle size reduction  
By reducing particle size, the increased surface area may improve the 
dissolution properties of the drug to allow a wider range of formulation approaches 
and delivery technologies. Conventional methods of particle size reduction, such as 
comminution and spray drying, rely upon mechanical stress to disaggregate the active 
compound (Ahuja Nitika et al., 2012). 
(6) Supercritical Fluid (SCF) Processes 
A SCF is a substance that exists above its critical point, which is defined by 
the conditions of temperature and pressure at which liquid and gaseous states of a 
substance coexist. When a liquid is heated, its density continues to decrease, while the 
density of vapor being formed continues to increase.  At the critical point, densities of 
liquid and gas are equal and there is no phase boundary, as shown in Figure (e). 
Above the critical point that is, in the supercritical region, the fluid possesses the 
penetrating power typical of a gas and the solvent power typical of a liquid.   
Supercritical fluid methods are mostly applied with carbon dioxide (CO2), 
which is used as either a solvent for drug and matrix or as an antisolvent. When 
supercritical CO2 is used as solvent, matrix and drug are dissolved and sprayed 
through a nozzle, into an expansion vessel with lower pressure and particles are 
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immediately formed. The adiabatic expansion of the mixture results in rapid cooling. 
This technique does not require the use of 
 
organic solvents and since CO2 is considered environmentally friendly, this 
technique is referred to as „solvent free‟. The technique is known as Rapid Expansion 
of Supercritical Solution (RESS). However, the application of this technique is very 
limited, because the solubility in CO2 of most pharmaceutical compounds is very low 
(<0.01 wt-%) and decreases with increasing polarity (Bhawana Kapoor et al., 2012) 
 
 
Fig (e): Supercritical region                            Fig 7: Schematic of the RESS apparatus                  
                                                                                   used in compound supercritical    
                                                                                   fluid technology                                                                                                                                          
(g) Kneading 
In this method a mixture of drug and carrier is wetted with methanol and 
kneaded thoroughly for 30 minutes in a glass mortar. The paste is dried under vacuum 
for 24 hours. Dried powder is passed through sieve no. 60 and stored in a dessicator 
(Prabhakar Shirse et al., 2012)  
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(8) Inclusion Complexes 
 The improvement in solubilisation ability within these water soluble 
polymer/drug included CD aggregates requires less cyclodextrin to solubilise the 
same amount of drug, reducing the volume constraints present for non-aggregated 
CDs and increasing the range of delivery technologies available.  Drug-CD 
complexes are commonly formed through either supersaturating a CD solution with 
drug and mildly agitating the solution for an extended period of time, or adding a 
mass of drug to a CD and solvent slurry and „kneading‟ to produce a paste which is 
then dried and sieved. 
 
Figure (f): Cyclodextrin [polymer]-drug complex 
APPLICATIONS OF SOLID DISPERSIONS  
To increase the solubility of poorly soluble drugs thereby increase the dissolution rate, 
absorption and bioavailability.  
1. To stabilize unstable drugs against hydrolysis, oxidation, recrimination, 
isomerisation, photo oxidation and other decomposition procedures.  
2. To reduce side effect of certain drugs.  
3. Masking of unpleasant taste and smell of drugs.  
4. Improvement of drug release from ointments, creams and gels.  
5. To avoid undesirable incompatibilities.  
6. To obtain a homogeneous distribution of a small amount of drug in solid state.  
7. To dispense liquid (up to 10%) or gaseous compounds in a solid dosage.  
8. To formulate a fast release primary dose in a sustained released dosage form.  
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9. To formulate sustained release regimen of soluble drugs by using poorly 
soluble or insoluble carriers.  
10. To reduce pre-systemic inactivation of drugs like morphine and progesterone 
(Arunachalam et al., 2010). 
Direct Capsule Filling- 
The filling of semisolid materials into hard gelatin capsules as melts, which 
solidify at room temperature, was first done in 1978. It was not until much later that 
the potential application of the technique for solid dispersions was fully realized. 
Laboratory scale semiautomatic equipment and large scale manufacturing equipment 
for direct capsule filling are commercially available. Direct filling of hard gelatin 
capsules with the liquid melt of solid dispersions avoids grinding-induced changes in 
the crystallinity of the drug. For example, the filling of hard gelatin capsules has been 
feasible in molten dispersions of triamterene-PEG 1500 using a Zanasi LZ 64 capsule 
filling machine (Zanasi Co, Bologna, Italy)  
 Electrostatic Spinning Method-  
Electro spinning is a process in which solid fibers are produced from a 
polymeric fluid stream solution or melt delivered through a millimeter-scale nozzle. 
This process involves the application of a strong electrostatic field over a conductive 
capillary attaching to a reservoir containing a polymer solution or melt and a 
conductive collection screen. Upon increasing the electrostatic field strength up to but 
not exceeding a critical value, charge species accumulated on the surface of a pendant 
drop destabilize the hemispherical shape into a conical shape (commonly known as 
Taylor‟s cone). Beyond the critical value, a charged polymer jet is ejected from the 
apex of the cone (as a way of relieving the charge built-up on the surface of the 
pendant drop). The ejected charged jet is then carried to the collection screen via the 
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electrostatic force. The columbic repulsion force is responsible for the thinning of the 
charged jet during its trajectory to the collection screen. The thinning down of the 
charged jet is limited by the viscosity increase, as the charged jet is dried. This 
technique has tremendous potential for the preparation of nanofibres and controlling 
the release of biomedicine, as it is simplest, the cheapest. This technique can be 
utilized for the preparation of solid dispersions in future. 
Surface-active Carriers- 
A surface-active carrier may be preferable in almost all cases for the solid 
dispersion of poorly water-soluble drugs. The surface active and self-emulsifying 
carriers for solid dispersion of poorly water-soluble drugs have been of great interest 
in recent years. Adsorption of surfactant on solid surface can modify their 
hydrophobicity, surface charge, and other key properties that govern interfacial 
processes such as flocculation/dispersion, floatation, wetting, solubilization, 
detergency, and enhanced oil recovery and corrosion inhibition. Surfactants have also 
been reported to cause solvation/plasticization, manifesting in reduction of melting 
the active pharmaceutical ingredients, glass transition temperature and the combined 
glass transition temperature of solid dispersions.  
Melt agglomeration process  
This technique has been used to prepare solid dispersion where the binder acts 
as a carrier. In addition, solid dispersions are prepared either by heating binder, drug 
and excipients to a temperature above the melting point of the binder (melt in 
procedure) or by spraying a dispersion of drug in molten binder on the heated 
excipients (spray on procedure) by using a high shear mixer. The effect of binder 
type, method of manufacturing and particle size are critical parameters in preparation 
of solid dispersions by melt agglomeration. It has been investigated that the spray on 
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procedure with PEG-3000, Poloxamer 188 and gelucire 50/13 attributed to immersion 
mechanism of agglomerate formation and growth. In addition, the melt in procedure 
also results in homogeneous distribution of drugs in agglomerate. (Bhawana Kapoor 
et al., 2012). 
 
CHAPTER II 
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CHAPTER II 
FAST DISSOLVING TABLET-REVIEW 
Oral routes of drug administration have wide acceptance up to 50-60% of total 
dosage forms. Solid dosage forms are popular because of ease of administration, 
accurate dosage, self medication, pain avoidance and most importantly the patient 
compliance. The most popular solid dosage forms are being tablets and capsules;  
 
Fast dissolving tablets are those when put on tongue disintegrate 
instantaneously releasing the drug which dissolve or disperses in the saliva. The faster 
the drug dissolves into solution, quicker the absorption and onset of clinical effect. 
Some drugs are absorbed from the mouth, pharynx and esophagus as the saliva passes 
down into the stomach. In such cases, bioavailability of drug is significantly greater 
than those observed from conventional tablets dosage form. The advantage of mouth 
dissolving dosage forms are increasingly being recognized in both, industry and 
academics. Their growing importance was underlined recently when European 
pharmacopoeia adopted the term “Orodispersible tablet” as a tablet that to be placed 
in the mouth where it disperses rapidly before swallowing. According to European 
pharmacopoeia, the ODT should disperse/disintegrate in less than three minutes.   
 
The basic approach in development of FDT is the use of superdisintegrants 
like cross linked carboxymethyl cellulose (croscarmellose), sodium starch glycolate 
(primogel, explotab), polyvinylpyrollidone (polyplasdone) etc, which provide 
instantaneous disintegration of tablet after putting on tongue, their by release the drug 
in saliva. The bioavailability of some drugs may be increased due to absorption of 
drug in oral cavity and also due to pregastric absorption of saliva containing dispersed 
drugs that pass down into the stomach. More ever, the amount of drug that is 
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subjected to first pass metabolism is reduced as compared to standard tablet. The 
technologies used for manufacturing fast-dissolving tablets are freeze-drying, spray-
drying, tablet molding, sublimation, sugar-based excipients, tablet compression, and 
disintegration addition. As a result of increased life expectancy, the elderly constitute 
a large portion of the worldwide population today. These people eventually will 
experience deterioration of their physiological and physical abilities (Debjit Bhowmik 
et al., 2009). 
 
Criteria for Fast dissolving Drug Delivery System:  
The tablets should   
 Not require water to swallow, but it should dissolve or disintegrate in the 
mouth in matter of seconds. 
 Be compatible with taste masking.   
 Be portable without fragility concern. 
 Have a pleasant mouth feel.  
 Leave minimum or no residue in the mouth after oral administration. 
 Exhibit low sensitive to environmental condition as temperature and 
humidity. 
 Allow the manufacture of the tablet using conventional processing and 
packaging equipments at low cost.  
Salient Features of Fast Dissolving Drug Delivery System: 
 Ease of Administration to the patient who can not swallow, such as the 
elderly, stroke victims, bedridden patients, patient affected by renal failure 
and patient who refuse to swallow such as pediatric, geriatric & 
psychiatric patients.  
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 No need of water to swallow the dosage form, which is highly convenient 
feature for patients who are traveling and do not have immediate access to 
water.  
 Rapid dissolution and absorption of the drug, which will produce quick 
onset of action. 
 Some drugs are absorbed from the mouth, pharynx and esophagus as the 
saliva passes down into the stomach. In such cases bioavailability of drug 
is increased. 
 Pregastric absorption can result in improved bioavailability and as a result 
of reduced dosage; improve clinical performance through a reduction of 
unwanted effects.   
 Good mouth feel property helps to change the perception of medication as 
bitter pill particularly in pediatric patient. 
 The risk of chocking or suffocation during oral administration of 
conventional formulation due to physical obstruction is avoided, thus 
providing improved safety. 
 New business opportunity like product differentiation, product promotion, 
patent extensions and life cycle management.  
 Beneficial in cases such as motion sickness, sudden episodes of allergic 
attack or coughing, where an ultra rapid on set of action required. 
 An increased bioavailability, particularly in cases of insoluble and 
hydrophobic drugs, due to rapid disintegration and dissolution of these 
tablets. 
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 Stability for longer duration of time, since the drug remains in solid dosage 
form till it is consumed. So, it combines advantage of solid dosage form in 
terms of stability and liquid dosage form in terms of bioavailability.  
Benefits of fast dissolving tablets 
 Administered without water, anywhere, any time. 
 Suitability for geriatric and pediatric patients, who experience difficulties 
in swallowing and for the other groups that may experience problems 
using conventional oral dosage form, due to being mentally ill, the 
developmentally disable and the patients who are un-cooperative, or are on 
reduced liquid intake plans or are nauseated.  
 Beneficial in cases such as motion sickness, suede episodes of allergic 
attack or coughing, where an ultra rapid onset of action required.  
 An increased bioavailability, particularly in cases of insoluble and 
hydrophobic drugs, due to rapid disintegration and dissolution of these 
tablets.  
 Stability for longer duration of time, since the drug remains in solid dosage 
form till it is consumed. So, it combines advantage of solid dosage form in 
terms of stability and liquid dosage form in terms of bioavailability.  
 
Limitations of Mouth Dissolving Tablets  
 The tablets usually have insufficient mechanical strength. Hence, careful 
handling is required.  
 The tablets may leave unpleasant taste and/or grittiness in mouth if not 
formulated properly (Debjit Bhowmik et al., 2009) 
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TECHNIQUES FOR PREPARING FAST DISOLVING TABLETS: 
Many techniques have been reported for the formulation of fast dissolving 
tablets or orodispersible tablets.  
1) Freeze drying / lyophilization 
2) Tablet Moulding 
3) Spray drying 
4) Sublimation 
5) Direct compression 
6) Mass extrusion  
 
Freeze-Drying or Lyophilization 
  This technique creates an amorphous porous structure that can dissolve 
rapidly. The active drug is dissolved or dispersed in an aqueous solution of a 
carrier/polymer. The mixture is done by weight and poured in the walls of the 
preformed blister packs. The trays holding the blister packs are passed through liquid 
nitrogen freezing tunnel to freeze the drug solution or dispersion. Then the frozen 
blister packs are placed in refrigerated cabinets to continue the freeze-drying. After 
freeze-drying the aluminum foil backing is applied on a blister-sealing machine.  
 
Tablet Molding: 
Molding process is of two types i.e. solvent method and heat method. Solvent 
method involves moistening the powder blend with a hydro alcoholic solvent 
followed by compression at low pressures in molded plates to form a wetted mass 
(compression molding). The solvent is then removed by air-drying. The tablets 
manufactured in this manner are less compact than compressed tablets and posses a 
porous structure that hastens dissolution.  
CHAPTER II                                              FAST DISSOLVING TABLET-REVIEW 
 
Ormeloxifene FDT Reg. No: 261211307 Page 25 
 
The heat molding process involves preparation of a suspension that contains a 
drug, agar and sugar (e.g. mannitol or lactose) and pouring the suspension in the 
blister packaging wells, solidifying the agar at the room temperature to form a jelly 
and drying at 30
○
C under vacuum. The mechanical strength of molded tablets is a 
matter of great concern. Binding agents, which increase the mechanical strength of 
the tablets, need to be incorporated. Taste masking is an added problem to this 
technology.  Compared to the lyophillization technique, tablets produced by the 
molding technique are easier to scale up for industrial manufacture.  
 
Spray Drying: 
In this technique, gelatin can be used as a supporting agent and as a matrix, 
mannitol as a bulking agent and sodium starch glycolate or crosscarmellose or 
crospovidone are used as superdisintegrants. Tablets manufactured from the spray-
dried powder have been reported to disintegrate in less than 20 seconds in aqueous 
medium. The formulation contained bulking agent like mannitol and lactose, a 
superdisintegrant like sodium starch glycolate & croscarmellose sodium and acidic 
ingredient (citric acid) and/or alkaline ingredients (e.g. sodium bicarbonate). This 
spray-dried powder, which compressed into tablets showed rapid disintegration and 
enhanced dissolution.  
 
Sublimation: 
   To generate a porous matrix, volatile ingredients are incorporated in the 
formulation that is later subjected to a process of sublimation. Highly volatile 
ingredients like ammonium bicarbonate, ammonium carbonate, benzoic acid, 
camphor, naphthalene, urea, urethane and phthalic anhydride may be compressed 
along with other excipients into a tablet. This volatile material is then removed by 
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sublimation leaving behind a highly porous matrix. Tablets manufactured by this 
technique have reported to usually disintegrate in 10-20 sec. Even solvents like 
cyclohexane; benzene can be used as pore forming agents.   
 
Direct Compression: 
   Direct compression represents the simplest and most cost effective tablet 
manufacturing technique. This technique can now be applied to preparation of ODT 
because of the availability of improved excipients especially superdisintegrants and 
sugar based excipients. 
 
(a) Superdisintegrants: 
In many orally disintegrating tablet technologies based on direct compression, 
the addition of superdisintegrants principally affects the rate of disintegration and 
hence the dissolution. The presence of other formulation ingredients such as water-
soluble excipients and effervescent agents further hastens the process of 
disintegration.   
 
(b) Sugar Based Excipients: 
This is another approach to manufacture ODT by direct compression. The use 
of sugar based excipients especially bulking agents like dextrose, fructose, isomalt, 
lactilol, maltilol, maltose, mannitol, sorbitol, starch hydrolysate, polydextrose and 
xylitol, which display high aqueous solubility and sweetness, and hence impart taste 
masking property and a pleasing mouthfeel. Mizumito et al have classified sugar-
based excipients into two types on the basis of molding and dissolution rate. 
Type 1: 
Saccharides (lactose and mannitol) exhibit low mouldability but high 
dissolution rate. 
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Type 2: 
Saccharides (maltose and maltilol) exhibit high mouldability and low 
dissolution rate.  
 
Mass-Extrusion: 
   This technology involves softening the active blend using the solvent mixture 
of water-soluble polyethylene glycol and methanol and subsequent expulsion of 
softened mass through the extruder or syringe to get a cylinder of the product into 
even segments using heated blade to form tablet. The dried cylinder can also be used 
to coat granules for bitter drugs and thereby achieve taste masking. (Shailesh Sharma, 
2008 & Debjit Bhownmik et al., 2009) 
 
EVALUATION OF FAST DISSOLVING TABLETS: 
Preformulation Studies: 
 Bulk density 
 Tapped density 
 Angle of repose 
 Carr’s index or % Compressibility 
 Hausner ratio 
 Precompression drug content 
Post compression studies: 
 Weight variation 
 Hardness 
 Thickness 
 Friability 
 Wetting time 
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 Water absorbtion ratio 
 Disntegration test 
 Invitro dreg release study 
 Solubility test 
 Stability studies 
CHAPTER III 
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CHAPTER III 
LITERATURE REVIEW 
Shaimaa N.Abd Alhammid et al., 2013, studied for formulation and evaluation of 
Rosuvastatin  Orodispersible tablet prepared by  using a super disintagrant 
croscarmillose, sodium starch glycolate and crospovidone  to enhance the 
disintegration and dissolution. Many trails were made to prepare an ODT by direct 
compression and wet granulation method. Overall result showed that crospovidone 
was the best super disintegrant on showing the shortest disintegration time and 
manitol was the best diluents in preparing Rosuvastatin Orodispersible tablet. 
Formulation containing 15 % crospovidone showed best drug release profile. 
Mohan kumar et al., 2013, reviewed solubility enhancement techniques. The various 
technological strategies reported in this literature, like solid dispersion, 
polymorphisim, complexation, hydrotrophy, co-solvency, pH adjustment, use of salt 
form, use of precipitation inhibitors, eutectic mixture, miceller solubilisation, super 
critical fluid technique, micronization, use of surfactants and newer techniques like 
Nano technology approaches, self emulsifying drug delivery system, solid lipid nano 
particle, and cryogenic technology. The present review described various novel 
techniques for enhancing drug solubility and improving bioavailability. 
Payal H.Patil et al., 2013, studied on solubility enhancement of Roloxifene using 
inclusion complex and cogrinding method. The study work was to enhance the 
solubility and dissolution of water insoluble drug Rolaxifene Hcl. The first approach 
drug was kneaded with hydroxyl propyl betacyclodextrin (HPBCD) and in the second 
one was co-grinded with modified guar gum (MGG). The result showed the inclusion 
complex method has produced better results as compare to other methods and thus 
was found to be more effective than co grinding method. 
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Abhilash M et al., 2013, formulated and evaluated of solid dispersion of Melitracen. 
In this study the drug has low solubility which results poor bioavailability. In the 
present study was an attempt to increase solubility by solid dispersion technique. The 
best formulation was compressed in to fast dissolving tablets using crospovidone as a 
super disintagrant by direct compression technique. The highest invitro drug release 
was observed in Betacyclodextrin solid dispersion ratio of 1:3 drug and carrier. 
Thakur Anil Kumar et al., 2013, studied on various techniques enhancing 
bioavailability of poorly water soluble drugs. This article described various methods 
to enhance solubility like encapsulation with cyclodextrin, nano technology 
approaches and hydrotrophy. The described techniques alone or in combination can 
be used to enhance the solubility of drugs. Selection of solubility enhancement 
method depends upon drug characteristic like solubility, chemical nature, melting 
point, absorption site, physical nature and pharmacokinetic behavior. 
Debjit et al., 2013, reviewed recent trends of polymer usage in the formulation of 
orodispersible tablets. The present study comprised the various kinds of disintagrants 
and superdisintagrants, which were used in the formulations to provide the safer and 
effective drug delivery with patient’s compliance.  
Chaudhary V.B and Pate J.K., 2012, developed a formulation of inclusion complex 
to enhance the solubility of poor water soluble drugs. complexation with cyclodextrin 
by different methods like physical mixing, melting , kneading, spray drying , co 
precipitation has been reported to enhance the solubility, dissolution rate  and 
bioavailability of poorly soluble drugs. 
Ravi S Wanare and Ravikant S Murkute., 2012, developed a  formulation and 
evaluation of Azithromycin fast dissolving tablet by wet granulation method. In this 
study fast dissolving tablet formulated with various super disintegrants such as 
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croscarmellose sodium, sodium starch glycolate and crospovidone. In all the 
formulation water was used as a binding agent.  Amongst all formulation formula F7 
containing sodium starch glycolate- 30mg produced least disintegrating time of 21.4 
seconds and faster dissolution.  
Anas Bahnassi et al., 2012, formulated aceclofenac fast dissolving tablet. The poor 
hydrophilicity of the drug results in variable dissolution rate and poor bio availability. 
The aceclofenac orodispersible tablet was prepared by using various types of 
disintegrants. Formulation containing plasdone xl 100 30 mg showed comparatively 
better drug release and disintegration time profile. 
Prabhakar Shires et al., 2012, formulated and evaluated cyclodextrin inclusion 
complex of glimipride tablet. The rationale of this study was to enhance the solubility 
& dissolution of the drug by prepared its complex with ßcd and hp-ß-cd. In the 
present study was an attempt to formulate and characterize inclusion complexes of 
glimepiride with ß-cd and hp-ß-cd. The inclusion complexes were prepared by three 
different methods viz. Physical, kneading and coprecipitation method. The inclusion 
complex containing glimipride: ß-cd and hp-ß-cd was further formulated into tablets 
by direct compression technique using super-disintegrants like crospovidone and 
microcrystalline cellulose. The prepared tablets were characterized using FT IR , DSC 
study and other evaluations. 
Amit Modi et al., 2012, developed a formulation and evaluation of diclofenac sodium 
fast dissolving tablets using different super disintegrant like sodium starch glycolate, 
croscarmellose sodium and crosspovidone [poly plasdone XL] by direct compression 
method. The tablet were evaluated for weight variation, hardness, friability, 
disintegration time  wetting time, invitro dissolution studies and drug content. It was 
concluded that the batch which was prepared by using combination of crospovidone 
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and sodium starch glycolate as a super disintagrant shows excellent short 
disintegration time, enhanced dissolution rate,  and hence leas to improve efficacy and 
bioavailability of drug. 
Dhaval Shah et al., 2012, studied on development and characterization of mouth 
dissolving tablet of zolmitriptan tablets were prepared by direct compression method 
employing super disintegrants such as kyron T-314, crospovidone, croscarmellose 
sodium and sodium starch glycolate. Prepared zolmitripan mouth dissolving tablet 
containing kyron T-314 exhibited shortest disintegration time of 35 seconds. To 
further decrease the disintegration time, a sublimation technique was also used along 
with super disintegrants for the preparation of MDT. 
Parul Saini et al., 2012, reviewed natural polymers used in fast dissolving tablets. 
The aim of the article was to study the natural polymers used in FDT formulation . 
Natural polymers like magnifera indica gum, hibiscus rososinenses mucilage, 
dehydrated banana powder, orange peel pectin,locustnbean gum, which improved the 
properties of tablet and also used as a binder and diluents.  Natural polymers are 
obtained easily from the natural origin and they are cost effective, nontoxic 
biodegradable, eco friendly devoid of any side effect renewable and also provide 
nutrinal supplements. 
Abdul Hasan Sathali A. and Selvaraj V., 2012, studied the enhancement of 
solubility and dissolution rate of racecadotril. Solid dispersion of racecadotril was 
prepared with carriers of poly vinyl pyrrolidone k 30, poly ethylene glycol 6000 and 
poloxamer 188 by using kneading, melting, solvent evaporation, freeze drying and 
physical mixture. The interaction between drug and carrier was evaluated by Fourister 
Transform infra red (FT IR) and Differential scanning colorimetry  studies, powder x- 
ray diffraction (PXRD) studies were also carried out the crystallinity of solid 
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dispersion. The results indicated drug and carrier (PVP K- 30) 1:3 ratio by kneading 
method produced best release. 
Karthikeyan et al., 2012, developed a formulation of diclofenac tablets for rapid pain 
relief. The object of the project was to get fast pain relief. Fast dissolving tablet was 
prepared by direct compression method using indion 214, indion 234, indion 244 and 
crosscarmellose as super disintegrant , micro crystalline cellulose was used as a 
diluents and manitol as a sweating agent. The formulation containing indion 244 
showed quick disintegration time of 29.66 seconds. Indion 244 was found to have 
high superdisintegrant property. 
Devandra Revanal Rane et al., 2012, studied on formulation and evaluation of fast 
dissolving tablet of albendazole. The main object of the study was to formulate fast 
dissolving and improving bioavailability of the drug. Fast dissolving tablet prepared 
by direct compression method using super disintegrant crospovidone, croscarmellose 
sodium in different concentration. Among all the formulation containing 5%
w
/w super 
disintagrant crospovidone and 20% 
w
/w MCC was considered to be best formulation 
which release was up to 99.09% in 40 seconds.   
Hyma .P et al., 2012 , studied  on improvement of solubility and dissolution rate of 
pioglitazone by solid dispersion technique. Pioglitazone is a poor water solubility 
drugs. The main objective of the study was to develop solid dispersion with polymers 
like polyethylene glycol – 4000, PEG – 6000, in the ratio 1:1, 1:2, 1:3, 1:4 and 1:5 by 
solvent evaporation technique.  The solid dispersion with PEG – 6000 [1:5] ratio 
showed best drug release where compare to solid dispersion with PEG- 4000 and 
other polymers. 
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Ashish Kumargarg et al, 2012, reviewed mouth dissolving tablets significants, Ideal 
properties of MDT, challenges in formulation, various formulation methods, list of 
super disintegrants and evaluation methods. 
Claudia Yanez et al., 2012, developed a cyclodextrin inclusion complex to improve 
physicochemical properties of herbicide bentazon. The inclusion complex prepared by 
two methods, kneading and freeze drying. Formulation characterization was 
investigated by different analytical techniques including Fourier transform infra red 
spectroscopy (FT IR), Diffential thermal analysis (DTA), X- ray diffractometry 
(XRD) and differential pulse voltametry (DPV). The result indicated inclusion 
complex by cyclodexrin shows improved physiochemical properties compare to free 
bentazon. 
Anjan K.Mahapatra et al.,2012, described an overview of theoretical definitions and 
technical approaches was broadly covered (technologies and hydrophilic carriers 
used). Further part of manuscript is committed to the formulation, analytical methods 
for characterization of samples, dissolution or release kinetics and model fittings. 
Imran Shekh et al., 2011, developed a preparation and characterization of 
betacyclodextrin with aspirin inclusion complex. The aim of the work was to study 
the influence of betacyclodextrin on asprin. The best formulation was 
betacyclodextrin and asprin solid dispersion, 1:2  drug and carrier ratios showed best 
drug release of 96.05%. 
Saravanakumar et al, 2011, reviewed fast dissolving tablets background, trends and 
future. This article described ideal properties of mouth dissolving tablets, mechanism 
of disintagrtion, method of preparing fast dissolving tablets, preformulation studies, 
evaluation studies and various patented fast dissolving tablet technologies.. 
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Ashish.P et al., 2011, reviewed on formulation of mouth dissolving tablet. The aim of 
this article was to review the progress of the evolving technologies and super 
disintegrating agents in the formulation, manufacturing and evaluation of tablets. This 
article was also discussed the evaluation methodologies for orally disintegrating 
tablets. In the present review described the formulation techniques and different 
evaluation techniques are discussed. 
Anupama singh et al., 2011, studied on evaluation and enhancement of solubility of 
paracetamol by solid dispersion technique using different polymer concentration. The 
aim of the study was to prepare characterize and compare solid dispersion of 
paracetamol using PEG – 4000 and polyvinyl pyrolidone used for enhancing the 
dissolution rate of drug. The solid dispersion was prepared by physical mix method 
and kneading method at 1:1, 1:2 and 2:1, ratio of drug and polymer, based on the drug 
release pattern the kneading method showed more drug release as compare to physical 
mixture. 
Nagendra Rao R et al., 2011, designed a solubility and dissolution enhancement of 
Cefixime using natural polymer by solid dispersion.. In the present work was an 
attempt to increase the solubility of cefixime by preparing solid dispersion using 
natural polymers (i.e.) guar gum. Various techniques used for preparing solid 
dispersion by Physical mixture, kneading and solvent evaporation method using 
different drug polymer ratio. Thus prepared solid dispersion was evaluated for 
percentage of yield, drug content, saturation solubility and invitro dissolution studies. 
Among the various methods comparison  kneading method produced best drug release 
profile. 
Shobhit Kumar et al., 2011, studied on aceclofenac dissolution rate enhancement by 
solid dispersion technique. The aim of the study was to prepare and characterizes 
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solid dispersion of aceclofenac employing a mixed excipient system, used composed 
of lactose, corn starch as a carrier. The solid dispersion were prepared by physical 
mixture method and solvent wetting methods using 1:1 ratio of drug to mixed 
excipient system. Best formulation selection was based on the drug release pattern, 
the solvent wetting method showed more invitro drug release as compare to physical 
mixture method. 
Seitia Anupama et al., 2011, studied design, optimization, preparation and evaluation 
of albendazole using factorial design. The objective of the study was to enhance the 
solubility and dissolution rate of albendazole, a poor water soluble anthelmintic drug, 
by preparation of solid dispersions. The dispersion granules were prepared using a hot 
melting technique which involved preparation of a homogenous dispersion of 
albendazole in gelucire 44/14 and PEG 8000. A two-factor, four-level (4*2) statistical 
design was implemented to quantitate the influence of gelucire 44/14 and PEG 8000 
on the dissolution profile, where gelucire 44/14 and PEG 8000 were chosen as 
independent variables, while T10 min (cumulative drug release in 10 minutes) and 
T60 min (cumulative drug release in 60 minutes) were chosen as dependent variables. 
The solid dispersions were characterized for their in-vitro dissolution rate. The 
optimized formulation was further characterized by DSC, XRD and SEM analysis. In 
conclusion the statistical model enabled us to understand the effects of formulation 
variables on the dispersion 
Yogesh S Thorat et al., 2011, reviewed a study on solubility enhancement technique- 
of conventional and novel approaches. This article described bioavailability issues; it 
can be due to insufficient solubility, thus leads to low permeability. Pharmaceutically 
the bioavailability approaches to correct with chemical approaches, which are also  
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time consuming process, each technique has several merits and demerits. In this 
review study was an attempt of comparing the conventional and novel techniques. 
Jagadevappa patil et al., 2010, study has performed with the intension of finding the 
effect simvastatin preparation with beta cyclodextrin and hydroxyl propyl beta 
cyclodextrin inclusion complex. The method of preparation of complex was simple 
physical mixture, kneading method, and spray drying method. They done following 
evaluations drug content, Aqueous solubility and invitro drug release studies. 
Conclusion exhibits Spray drying method were shown better solubility then other 
methods.  
Tomar V et al., 2010, developed a formulation for Enhancement of solubility of 
Acyclovir by solid dispersion and inclusion complex method. The solubility of 
Acyclovir was found to be more with inclusion complex as compare to solid 
dispersion technique. The result showed that hydroxy propyl betacyclodextin 
inclusion complex could possibly improved the dissolution characteristics of 
acyclovir (1:5 ratio) shows better release then other formulations. 
Sawarikar P.P et al., 2010, the investigation aim was to develop and evaluate 
inclusion complex of isoxuprine hydrochloride with betacyclodextrin using kneading 
and co precipitation method. The resultant product was used to prepare Fast 
dissolving tablet by using super disintegrants like Sodium starch glycolate, 
croscarmelose (ac-di-sol) and crospovidone by direct compression method. The 
formulation containing Ac di sol 5% showed complete release of drug within 4 
minutes. 
Suhas M.Kakade et al., 2010, developed a formulation and evaluation of mouth 
dissolving tablets of losartan potassium. Mouth dissolving tablets prepared by direct 
compression method using super disintegrants like Polyplasdone xl 10, croscamellose 
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sodium and explotab in different concentration and evaluated for the pre compression 
parameters such as bulk density, compressibility, angle of repose etc. among all the 
formulation    5% 
w
/w super disintegrant  polyplasdone XL-10 was consider to be best 
formulation which release up to 99.26% in 12 minutes. 
Jeevana Jyothi.B and Suneela G., 2010, formulated a fast dissolving tablet of 
glibenclamide using crospovidone by its kneading method. The object of the work 
was to develop fast dissolving tablet of glibenclamide using crospovidone in ratio of 
1:0.5, 1:1, and 1:1.5. The tablet were prepared by using kneading mixture by wet 
granulation method. The mixture prepared in the ratio of drug and crospovidone as 
1:1.5 by kneading method shows best release.  
Arun Prasad K et al., 2010, formulated and evaluated of solid dispersion of 
Terbinafine hydrochloride. The study was aimed to formulate solid dispersion of 
terbinafine hydrochloride tablet by using carriers polyethylene glycol 6000 [ by 
melting method ] polyvinyl pyrrolidone K 30 [ by solvent method ] in the drug carrier 
ratio 1:1, 1:2, and 1:3. The prepared solid dispersion was characterized for drug 
content, thermal studies, FT IR, DSC, studies and dissolution. The solid dispersion 
showed better drug release profile which is chosen to formulate into a tablet dosage 
form. 
Appa Rao et al., 2010, developed a formulation and evaluation of aceclofenac Solid 
dispersion for dissolution rate enhancement. Solid dispersion of Aceclofenac were 
prepared by using lactose, manitol and urea to increase its aqueous solubility. The 
prepared solid dispersion was subjected for % of practical yield, drug content and IR 
studies. The maximum yield was found to be 97.92% in [ Aceclofenac : urea -7:3 
ratio ]. The drug release profile formulation 9:1 ratio [ Aceclofenac : Polymer Lactose 
]which showed best release. 
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Vineet Bhardwaj et al., 2010, The objective of the present study was to prepare the 
mouth dissolving tablet of Amlodipine using different superdisintegrants by 
sublimation method. Different concentrations 2%, 4% and 6% of superdisintegrants 
such as Ac-Di-Sol, sodium starch glycolate, Kollidon-CL were used respectively. 
Camphor was used as a sublimating agent. Tablets are prepared by direct compression 
method and mannitol is used as bulking agent. The compressed tablets are dried for 5 
hours to allow sublimation of camphor to increase the porosity of the fast dissolving 
tablets to improve the dissolution. The tablets were evaluated for hardness, friability, 
weight variation, wetting time, thickness, water absorption ratio, disintegrating time, 
uniformity of content and in-vitro drug release. Amongst all formulations, 6% Ac-Di-
Sol containing formulation showed least disintegrating time of 11sec.and faster 
dissolution. 
Kothawade et., al, 2010 investigation was an attempt made to improve the solubility 
and dissolution rate of a poorly soluble drug, telmisartan solid dispersions were 
prepared using Polyvinyl pyrrolidone (PVP), Polyethylene glycol-1500 (PEG-1500) 
and Polyethylene glycol-4000(PEG-4000) to increase its aqueous solubility. 
Telmisartan solid dispersions were prepared in 1:1, 1:2 and 1:4 ratios of the drug to 
polymer ratio   (by weight) using solvent evaporation method. The formulations were 
characterized for solubility parameters, drug content studies, drug release studies and 
drug-polymer interactions by using FTIR spectrum. Formulation containing 1:2 ratio 
of drug: PEG-4000 showed the best release with a cumulative release of 99.49% as 
compared to 35.82 % for the pure drug. 
Mohamed Gulzar Ahmed and et al., 2010, study was aimed to improving the 
dissolution of poorly water-soluble drug, aceclofenac. The solid dispersions were 
prepared in different proportions using hydrophilic carriers like Urea and Mannitol. 
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The dissolution rate studies were performed in both simulated gastric fluid and 
simulated intestinal fluid. It is observed that the dissolution was affected by the 
acidity of the medium. Solid dispersions gave faster dissolution rate when compared 
to corresponding physical mixture and pure drug, invivo absorption and anti-
inflammatory activity studies of solid dispersions also confirmed the above results. 
Deepthi Mathew et al., 2009, developed a Nimusulide – Betacyclodextrin complex 
in oral and topical dosage forms. The object of the project was to enhance the aqueous 
solubility of nimusulide by using aqueous solubility carriers.   Nimusulide – 
Betacyclodextrin solid complex are formulate by co precipitation method. The invitro 
drug release profile study showed dissolution of Nimusulide has improved, by 
complexation with BCD. The prepared complexes ware suitable for oral and topical 
formulations. 
Shukla Vikesh et al., 2009, studied the Influence of Betacyclodextrin complex on 
ketoprofen release from matrix formulation. The objective of this study was to 
improve dissolution profile and the bioavailability of the ketoprofen. The invitro 
release demonstrated that matrix tablet containing the ketoprofen  with 
betacyclodextrin solid complex displayed faster drug release compare with physical 
mixture and free drug. Formulation prepared by co- precipitation and kneaded 
ketoprofen with betacyclodextrin. The result indicated inclusion complex has faster 
dissolution rates. 
Debjit Bhowmik et al., 2009, presented a study  on overview on fast dissolving 
tablets. The article which describes the various methods to prepare fast dissolving 
techniques such as Freeze drying, Tablet molding, Spray drying, Sublimation, Direct 
compression, Mass extrusion and important patented technologies, evaluation 
methods, and brief about preformulation monitoring studies. 
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Daist Sharma et al., 2009, studied on solubility enhancement and reviews eminent 
role in poorly soluble drugs. The present review was devoted to production of solid 
dispersion with various carriers used and the advantageous properties of solid 
dispersion. 
Jain C.P and Smnaruka P, developed valsartan fast dissolving tablet formulation 
and evaluation. Fast dissolving tablet was prepared by direct compression method 
using super disintagrant crospovidone, croscarmelose sodium and  sodium starch 
glycolate . the result showed increase drug release by increase the concentration of 
super disintagrants and was found to be highest with formulation containing 
crospovidone.  
Brahmeshwar Mishra et al., 2009, this study was attempt to describe a detailed 
review on technological advances made so for in the area of evaluation of mouth 
dissolving tablets with respect to special characteristics of these unique dosage forms. 
In the absence of any available standardized method the author recommendation on 
critical issues in the field may be considered. 
Mohini and et al, 2009, The objective of this research was to formulate fast 
dissolving tablet of amlodipine besylate for rapid action. Sublimation method was 
adapted to prepare the tablets by using a 2 full factorial design. FT-IR and 
D.T.A studies revealed that there was no physico-chemical interaction between 
amlodipine besylate and other excipients. All formulations are evaluated for pre-
compression and post-compression parameters. The results indicate that the optimized 
tablet formulation provides a short DT of 8 sec with sufficient crushing strength and 
acceptable friability. 
Shallesh Sharma et al., 2008, formulated a new generation – Fast dissolving tablets. 
The study describes the importance of fast dissolving formulation and various 
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methods used to prepare fast dissolving tablets. This article describes the details on 
preformulation, evaluation and ingredient profile and its properties.  
Kamal Dua et al., 2007,  investigated study for norfloxacin  solubility with  presence 
of acidic solublizing additives. The study is aimed for improving the solubility of 
drugs. Norfloxacin has incorporating with solubilizing additives such a ascorbic acid 
and citric acid in to betacyclodeextrin complexes. It exhibits a higher solubility at p
H
 
below4 and above 8. In the present work betacyclodextrin were prepare along with 
solubilizing additives such as citric acid and ascorbic acid in proportion. The results 
has showed an enhanced dissolution rate both p
H
 1.2 and p
H 
7.4 media 
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CHAPTER IV 
AIM OF THE WORK 
Solubility of a drug is an important property that mainly influences the extent 
of oral bioavailability. The new chemical entities about 40% are poorly water-soluble. 
Unfortunately, many of these potential drugs are abandoned in the early stages of 
development due to solubility concerns. It is therefore becoming increasingly more 
important that, the methods for overcoming solubility limitations may be identified 
and applied commercially such that, the potential therapeutic benefits of these active 
molecules can be realized. 
 
Ormeloxifene is a selective estrogen receptor modulator drug, which is widely 
used for the management of dysfunctional uterine bleeding, contraceptive and 
emergency contraceptive. It is chemically 3, 4 trans 2, 2 dimethyl 3, phenyl-4(p) beta 
pyrrolidinoethoxy phenyl 7 methoxy chroman hydrochloride. 
 
One of the major problems with this drug is its very low solubility in 
biological fluids, which results into poor bioavailability after oral administration. It 
belongs to class II drug according to biopharmaceutical classification system (BCS), 
that is, low solubility and high permeability. It would be advantageous to increase the 
solubility of such molecule. Further it is important to enhance aqueous solubility and 
dissolution rate, which may lead to enhancement of bioavailability from its oral solid 
dosage form. 
 
In the formulation point of view conventional dosage forms (Tablets and 
capsules) take   higher disintegration time, so that the pharmacological action is 
delayed by 30-45 minutes from its administration. To overcome this problem tablets 
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that can rapidly disintegrate or dissolve (within one minute) in oral cavity have 
attracted a great deal of attention. 
      In this study comprise of two steps, the first step is to improve the aqueous 
solubility of ormeloxifene hydrochloride by solid dispersion technique, using 
polymers like betacyclodextrin and polyethylene glycol 6000 by solvent evaporation, 
melting, co-precipitation and kneading methods. 
       The second step is compression of fast dissolving tablet, by using the 
yield of best solid dispersion formulation with various super disintagrants like 
crospovidone, sodium starch glycolate and crosscarmellose sodium by direct 
compression technique. The best formulation selection is on the basis of drug release 
pattern, disintegration time, water absorption ratio, and wetting time. 
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CHAPTER V 
PLAN OF WORK 
I. PREPARATION OF STANDARD CALIBRATION CURVE 
a) Determination of λ-max for Ormeloxifene in Distilled water and                           
phosphate buffer pH 6.8. 
b)  Calibration of Ormeloxifene in distilled water  
c)  Calibration of Ormeloxifene in phosphate buffer pH 6.8. 
 
II. COMPATIBILITY STUDIES FOR DRUG AND EXCIPIENTS 
1) Fourier Transform Infra Red Spectroscopic (FT-IR) studies  
 
III. FORMULATION AND EVALUATION OF SOLID DISPERSIONS  
a. Formulation and evaluation of solid dispersion by different techniques. 
b. Determination of percentage of yield for all formulations  
c. Determination of drug content of all formulation  
d. Invitro dissolution studies of solid dispersion. 
e. Selection of best formulation based on the invitro drug release studies. 
 
IV.EVALUATION OF SELECTED FORMULATION 
a) Powder X-Ray Diffraction (PXRD) studies  
          b) Fourier Transform Infrared spectroscopic study of best formulation.   
c) Solubility study of solid dispersion.  
d) Differential Scanning Calorimetric (DSC) Studies 
 
V. PREFORMULATION STUDY FOR FAST DISSOLVING TABLETS   
 
CHAPTER V                                                                                     PLAN OF WORK 
 
Ormeloxifene FDT Reg. No: 261211307 Page 46 
 
VI. FORMULATION OF ORMELOXIFENEFAST DISSOLVING TABLET 
By direct compression method, using different superdisintagrants.  
 
VII. POST COMPRESSION EVALUATION OF FAST DISSOLVING 
TABLETS. 
 
VIII. BEST FORMULATION SELECTION 
 
IX. STABILITY STUDIES 
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CHAPTER VI 
MATERIALS AND EQUIPMENTS 
 
 
  
Material 
 
Supplier 
 
Ormeloxifene 
Gift sample from HLL Life care Ltd, 
Belgaum [KA] 
Beta cyclodextrin 
Hi Media Laboratories Pvt. Ltd, 
 Mumbai 
PEG – 6000 
S.D Fine chemicals Ltd, 
Mumbai 
Sodium starch glycolate 
High Purity Laboratory Chemicals Pvt. Ltd, 
Mumbai. 
Crospovidone 
Gift sample from Jersy Ethical’s, 
 Madurai 
Croscarmellose sodium 
Gift sample from Jersy Ethical’s, 
 Madurai 
Micro crystalline cellulose 
High Purity Laboratory Chemicals Pvt. Ltd, 
Mumbai. 
PVP K-30 
Shasun Pharmaceuticals Ltd, 
Pondicherry 
Mannitol 
Nice chemicals Pvt. Ltd, 
Cochin 
Magnesium Stearate 
High Purity Laboratory Chemicals Pvt. Ltd, 
Mumbai. 
Talc 
Universal scientific suppliers,  
Madurai 
Methanol 
Universal scientific suppliers,  
Madurai 
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Details of Equipments 
EQUIPMENTS SUPPLIERS 
 
Electronic Weighing Balance A&D Company, Japan. 
Single punch tablet compression machine 
Cadmach Machinery Co. Pvt, 
Ahmadabad. 
UV Visible spectrophotometer 
Shimazdu UV-1700, 
Japan. 
Digital tablet dissolution test apparatus 
Lab India Disso apparatus 2000, 
India. 
Friability test apparatus 
Indian Equipment corporation, 
Mumbai. 
Tablet hardness tester 
Praveen Enterprises, 
Bangalore. 
Vernier caliper 
Linker, 
Mumbai. 
Disintegration  test apparatus Rolex, India. 
Fourier transform infrared spectroscopy 
Shimadzu, 
Japan. 
Differential  scanning colorimeter 
DSC Q200 V24.4 Instrument , 
USA. 
Powder X-ray diffractometer 
XD, Shimadzu, 
Japan. 
Magnetic stirrer M.C. Dalal, Chennai. 
Mechanical shaker Secor, India. 
Environmental Chamber Inlab Equipments (P) Ltd, Chennai. 
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CHAPTER VII 
DRUG PROFILE 
Ormeloxifen HCl 
 
Synonym   : Centchroman 
 Structure   :    
 
   
 Formula   : C30H35NO3
 
 
 Molecular weight  : 457.604 g/mol 
Systematic iupac name       : 1-[2-[4-[(3S,4R)-7-methoxy-2,2-dimethyl-3-
phenyl-chroman-4-yl]phenoxy]ethyl] 
pyrrolidine 
 Appearance   : Off- white powder  
Solubility                             : Soluble in chloroform and methanol Sparinglly 
soluble in ethanol   (95 %) Very slightly soluble 
in water 
Melting point   :  212º c   to 218
o 
c                                                           
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 Log P    : 7.41  
Half life   :  4 Hours  
 Route of administration : Oral  
 Dose    :  
Contraception: 
30 mg twice a week for the 1st 12 weeks then 1 tablet (30 mg) 
once a week from 13th weeks onwards. Take 1st tablet on the 
1st day of menstrual cycle. Follow dose irrespective of 
menstrual periods. 
DUB: 
60 mg twice a week for the 1st 12 weeks and then 
60mg once a week for up to next 12 weeks. 
     Dosage form:  
                                  Tablets    ---   30 mg and 60 mg         
                         (Jawahar Lal, Elsevier, 2009) 
Pharmacodynamics:  
Ormeloxifene is a SERM, or selective estrogen receptor modulator. In some 
parts of the body, its action is estrogenic (e.g., bones), in other parts of the body, its 
action is anti-estrogenic (e.g., uterus, breasts.) It causes an asynchrony in the 
menstrual cycle between ovulation and the development of the uterine lining. It did 
not affect ovulation in the majority of women, while causing the lining of the uterus to 
build more slowly. 
It speeds the transport of any fertilized egg through the fallopian tubes more 
quickly than is normal. Presumably, this combination of effects creates an 
environment such that if fertilization occurs, implantation will not be possible. 
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Pharmacokinetics: 
Ormeloxifene is administered by the oral route, is well absorbed from the 
intestinal tract and Peak plasma levels are attained in about 4 hour and terminal half 
life of the drug is 170 hours. Protein binding is 90 % Safety in, lactation and renal / 
hepatic insufficiency is inadequate, which requires care in the usage.      
Absorption: 
centchroman is  rapidly absorbed, with a maximum serum concentration 
(Cmax) varying from 117 to129 ng/mL  and  it observed 4 h after drug ingestion. 
Distribution: 
Centchroman is widely distributed within the body due to its high lipid 
solubility in healthy women. The apparent volume of distribution is higher than the 
total body fluid and the mean residence time (MRT) is 128 days. Moreover, nursing 
females showed comparable Vd/F to that of non nursing females treated orally. 
Therefore, breastfeeding does not appear to affect the distribution of this drug. 
Centchroman binds strongly to serum albumin in healthy subjects (~90%) in the 
individual serum samples with inter subject variability in protein binding of 
centchroman. The binding increases with an increase in total protein content. 
Metabolism: 
centchroman is metabolized by rat liver homogenate in vitro to biologically 
active (7-desmethyl chroman, 2-desmethyl chroman and 2-monomethyl chroman) and 
inactive metabolites, with active metabolites contributing to estrogen agonistic and 
anti-implantation activities, while inactive metabolites accounting for its gradual 
metabolic disposition .  A marked increase in activity of hepatic microsomal aniline 
hydroxylase, aminopyrine N-demethylase, cytochrome P450 and cytochrome b, 
indicating rapid disposal of the compound from the body, has also been observed in 
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adult female rhesus monkeys treated with 25 mg/kg dose of centchroman 8 h before 
autopsy.  
Elimination: 
Studies regarding the metabolism of centchroman in humans are scarce. In 
serum and milk, the demethylated metabolite (7-desmethyl centchroman) has been 
reported after the oral administration of centchroman to healthy volunteers 
Drug–drug interactions: 
Co-administration of tetracycline yielded significantly higher C (35%) and a 
shorter time to reach Cmax(t) for centchroman (42%) than those obtained in the 
control group of females. Inclusion of lactic acid bacillus spores in the regimen 
resulted in similar effects with increase in Cmax (47%)  
Adverse effect:  
Delayed menses 
      (Jawahar Lal, Elsevier, 2009) 
 
 
CHAPTER VIII 
 
 
 
 
 
 
 
 
 
 
 
EXCIPIENTS PROFILE 
CHAPTER VIII                                                                     EXCIPIENTS PROFILE 
 
Ormeloxifene FDT Reg. No: 261211307 Page 53 
 
CHAPTER VIII 
EXCIPIENT PROFILE 
Betacyclodextrins 
Synonyms: 
 b-Cyclodextrin beta-cycloamylose 
 Beta-dextrin 
 Betadexum 
Empirical Formula  : C42H7035  
Molecular Weight  : 1135 
Structural Formula: 
 
Functional Category: 
Solubilizing agent; stabilizing agent. 
Pharmacopeial specifications  
Compressibility  : 0.523 g/cm 
Density (tapped)  : 0.754 g/cm 
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Solubility : Soluble 1 in 200 parts of propylene glycol, 1in50 of water at 
208C, 1 in 20 at 508C; practically insoluble in acetone, and ethanol (95%). 
Specific rotation   : D25= þ162.08; 
Surface tension (at 258C) n : 71 mN/m (71 dynes/cm); 
 Stability and Storage Conditions: 
β-Cyclodextrin is stable in the solid state if protected from high humidity. 
Cyclodextrins should be stored in a tightly sealed container, in a cool, dry place. 
 Method of Manufacture: 
Betacyclodextrin is produced by the action of the enzyme cyclodextrin 
glucosyltransferase upon starch or a starch hydrolysate. An organic solvent is used to 
direct the reaction that produces betacyclodextrin, and to prevent the growth of 
microorganisms during the enzymatic reaction. The insoluble complex of 
betacyclodextrin and organic solvent is separated from the non cyclic starch, and the 
organic solvent is removed in vacuum so that less than 1 ppm of solvent remains in 
the betacyclodextrin. The betacyclodextrin is then carbon treated and crystallized 
from water, dried, and collected. 
Safety: 
 nontoxic and nonirritant 
 cyclodextrins are  approved for use in food products and orally administered     
pharmaceuticals in a number of countries. 
 Cyclodextrins are not irritant to the skin and eyes, or upon inhalation.  
 There is also no evidence to suggest that cyclodextrins are mutagenic or 
teratogenic. 
Handling Precautions: should be handled in a well-ventilated environment. 
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CROSPOVIDONE 
SYNONYMS: 
 Crosslinked povidone 
 Kollidon  
 Polyplasdone  
 Polyvinylpolypyrrolidone 
 1-vinyl-2-pyrrolidinone homopolymer 
CHEMICAL NAME: 
1-Ethenyl-2-pyrrolidinone homopolymer 
EMPIRICAL FORMULA: 
(C6H9NO)n 
MOLECULAR WEIGHT: 
>1 000 000 
STRUCTURAL FORMULA: 
 
FUNCTIONAL CATEGORY: 
Tablet disintegrant. 
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DESCRIPTION: 
Crospovidone is a white to creamy white, finely divided, free flowing 
practically tasteless odorless or nearly odorless, hygroscopic powder.  
TYPICAL PROPERTIES: 
DENSITY: 
1.22g/ cm3. 
SOLUBILITY: 
Practically insoluble in water and most common organic solvents. 
PH (1%SUSPENSION):     
5.0-8.0 
RESIDUE ON IGNITION:   
≤0.4% 
MOISTURE CONTENT: 
Maximum moisture absorption is approximately 60%. 
METHOD OF MANUFACTURE: 
Acetylene and formaldehyde are reacted in the presence of a highly active 
catalyst to form butynediol, which is hydrogenated to butanediol and then 
cyclodehydrogenated to form butyrolactone. Pyrrolidone is produced by reacting 
butyrolactone with ammonia. This is followed by a vinylation reaction in which 
pyrrolidone and acetylene are reacted under pressure. The monomer vinylpyrrolidone 
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is then polymerized in solution, using a catalyst. Crospovidone is prepared by a 
‘popcorn polymerization’ process. 
STORAGE CONDITIONS: 
Since crospovidone is hygroscopic, it should be stored in an airtight container 
in a cool, dry place. 
HANDLING PRECAUTIONS: 
Observe normal precautions appropriate to the circumstances and quantity of 
material handled. Eye protection, gloves and dust mask are recommended 
INCOMPATIBILITIES: 
Crospovidone is compatible with most organic and inorganic pharmaceutical 
ingredients. When exposed to a high water level, crospovidone may form molecular 
adducts with some materials. 
SAFETY: 
Crospovidone is used in oral pharmaceutical formulations and is generally 
regarded as a nontoxic and nonirritant material. Short-term animal toxicity studies 
have shown no adverse effects associated with crospovidone. However, owing to the 
lack of available data, an acceptable daily intake in humans has not been specified by 
the WHO (Raymond C Rowe et al., 2006). 
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PEG-6000 
SYNONYM: 
Carbowax; Carbowax Sentry; Lipoxol; Lutrol E; PEG; Pluriol E; 
polyoxyethylene      glycol. 
STRUCTURE: 
 
CHEMICAL NAME: 
a-Hydro-o-hydroxypoly(oxy-1,2-ethanediyl) 
EMPIRICAL FORMULA: 
HOCH2(CH2OCH2)mCH2OH  
                 Where m represents the average number of oxyethylene groups. 
Alternatively, the general formula H(OCH2CH2)nOH may be used to represent 
polyethylene glycol, where n is a number m in the previous formula +1. 
MOLECULAR WEIGHT: 
                                 6000 
FUNCTIONAL CATEGORY: 
Ointment base; plasticizer; solvent; suppository base; tablet and capsule 
lubricant. 
DESCRIPTION:  
The USPNF 23 describes polyethylene glycol as being an addition polymer 
ethylene oxide and water. Polyethylene glycol grades 200–600 are liquids; grades 
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1000 and above are solids at ambient temperatures. Solid grades (PEG>1000) are 
white or off-white in color, and range in consistency from pastes to waxy flakes. They 
have a faint, sweet odor. Grades of PEG 6000 and above are available as free-flowing 
milled powders. 
PROPERTIES: 
Physical state  : white flakes 
 Solubility in water : soluble in water 
Solvent solubility: soluble in methanol, ethanol (95%), 
dichloromethane and acetone. 
HANDLING PRECAUTION: 
Observe normal precautions appropriate to the circumstances and quantity of   
material handled. Eye protection is recommended. 
STABILITY AND STORAGE CONDITIONS: 
Polyethylene glycols are chemically stable in air and in solution; Polyethylene 
glycols should be stored in well-closed containers in a cool, dry place. 
SAFETY: 
Polyethylene glycols are widely used in a variety of pharmaceutical 
formulations. Generally, they are regarded as nontoxic and nonirritant materials. 
Adverse reactions to polyethylene glycols have been reported, the greatest toxicity 
being with glycols of low molecular weight. However, the toxicity of glycols is 
relatively low.     
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CROSCARMELLOSE SODIUM 
Synonyms: 
 Ac-Di-Sol. 
 Cross linked carboxymethylcellulose sodium. 
  Explocel. 
  Modified cellulose gum. 
  Primellose. 
  Solutab. 
  Vivasol. 
Chemical Name: 
Cross linked carboxy methyl ether Cellulose sodium salt. 
Functional Category: 
Tablet and capsule disintegrant. 
Applications in Pharmaceutical Formulation: 
 Disintegrating agent for tablets and capsules. 
Description: 
-White or grayish white powder. 
-Odourless and tasteless. 
-Insoluble in water. Practically insoluble in acetone, ethanol and toluene. 
Pharmacopoeial Specifications: 
pH (1% w/v dispersion) 5.0–7.0 
Loss on drying 10% 
Heavy metals 10 ppm 
Sodium chloride and sodium glycolate  0.5% 
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Sulfated ash 14.0–28.0%  
Settling volume 10.0–30.0 ml 
Acidity/alkalinity: pH = 5.0–7.0 in aqueous dispersions. 
Density (bulk): 0.529 g/cm3  
Density (tapped): 0.819 g/cm3  
Density (true): 1.543 g/cm3 
Stability and Storage Conditions: 
Croscarmellose sodium should be stored in a well-closed container in a cool, 
dry place. 
Incompatibilities: 
 Croscarmellose sodium is not compatible with strong acids or with soluble 
salts of iron and some other metals such as aluminum, mercury, and zinc. 
Handling Precautions: 
Croscarmellose sodium may be irritant to the eyes; eye protection is 
recommended (Hand book of Pharmaceutical excipients-5
th
 edition, 211-213). 
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SODIUM STARCH GLYCOLATE 
Synonyms: 
 Explosol. 
 Explotab. 
 Primojel. 
 Starch carboxymethyl ether, sodium salt. 
 Tablo. 
 Vivastar P. 
Chemical Name: 
Sodium carboxymethylstarch. 
Chemical structure: 
 
Functional Category: 
Tablet and capsule disintegrant. 
Application in Pharmaceutical Formulation: 
 Sodium starch glycolate is  used as a disintegrant in capsule and tablet 
formulations. 
 Sodium starch glycolate is also used as a suspending vehicle. 
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Description: 
 Sodium starch glycolate is a white to off-white, odorless, tasteless, free 
flowing powder 
 It does not melt, but chars at approximately 200oC 
 It is sparingly soluble in ethanol (95%) but practically insoluble in water. 
Pharmacopoeial Specifications: 
 Specific surface area: 0.24m2/g; 
 Swelling capacity: In water, sodium starch glycolate swells to up to 300 
times its volume. 
 Viscosity (dynamic): 4200 mPa s (200 cP) for a 4% w/v aqueous 
dispersion. 
 Viscosity is 4.26 mPa s for a 2% w/v aqueous dispersion. 
Stability and Storage Conditions: 
 Sodium starch glycolate should be stored in a well-closed container in order 
to protect it from wide variations of humidity and temperature, which may cause 
caking. 
Incompatibilities: 
Sodium starch glycolate is incompatible with ascorbic acid. 
Handling Precautions: 
Sodium starch glycolate may be irritant to the eyes; eye protection and gloves 
are recommended (Hand book of Pharmaceutical excipients-5
th
 edition). 
 
 
 
CHAPTER VIII                                                                     EXCIPIENTS PROFILE 
 
Ormeloxifene FDT Reg. No: 261211307 Page 64 
 
MAGNESIUM STEARATE 
Synonyms: 
 Magnesium octadecanoat. 
 Octadecanoic acid, magnesium salt. 
 Stearic acid, magnesium salt. 
Chemical Name: 
Octadecanoic acid magnesium salt. 
Structural Formula: 
[CH3 (CH2)16COO]2Mg 
Molecular Structure: 
 
 
Empirical Formula and Molecular Weight: 
C36H70MgO4& 591.34 
Functional Category: 
Tablet and capsule lubricant. 
Application in Pharmaceutical Formulation: 
 Lubricant in capsule and tablet formulation.( 0.25% to  0.25%). 
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 Magnesium stearate is widely used in cosmetics, foods, and 
pharmaceutical formulations.  
  It is also used in barrier creams. 
Description: 
 Magnesium stearate is a very fine, light white powder. 
 Faint odour. 
 Characteristic taste. 
 Greasy to the touch and readily adheres to the skin.  
Pharmacopoeial Specifications: 
Freezing point 5538C 
Nickel 45 ppm 
Cadmium 43 ppm 
Loss on drying 46.0% 
Chloride 40.1% 
Sulfate 41.0% 
Lead 410 ppm 
Stability and Storage Conditions: 
            Magnesium stearate should be stored in a wellclosed container in a 
cool, dry place. 
Incompatibilities: 
Incompatible with strong acids, alkalis, and iron salts. Avoid mixing with 
strong oxidizing materials. Magnesium stearate cannot be used in products 
containing aspirin, some vitamins, and most alkaloidal salts. 
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Safety: 
Oral consumption of large quantities may produce a laxative effect or 
mucosal irritation.  
Handling Precautions: 
- Eye protection and gloves are recommended. 
-Excessive inhalation of magnesium stearate dust may cause upper 
respiratory tract discomfort, coughing, and choking (Hand book of Pharmaceutical 
excipients-5
th
 edition, 430-433). 
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MANNITOL 
Synonyms: 
 Cordycepic acid. 
 Manna sugar. 
 D-Mannite. 
  Pearlitol. 
Chemical Name: 
D-Mannitol. 
Chemical structure: 
 
 
Empirical Formula and Molecular Weight: 
C6H14O6 & 182.17 
Functional Category:  
 Diluent. 
 Sweetening agent. 
 Tonicity agent. 
Application in Pharmaceutical Formulation: 
 Mannitol is widely used in pharmaceutical formulations and food 
products.  
 It is used asdiluents (10–90% w/w) in tablet formulations. 
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 Mannitol is commonly used as an excipient in the manufacture of 
chewable tablet formulations. 
 Plasticizer in soft-gelatin capsules, as a component of sustained-release 
tablet formulation. 
 It is used as a carrier in dry powder inhalers. 
 It is also used asdiluents in rapidly dispersing oral dosage forms. 
 It is used in food applications as a bulking agent. 
Description: 
 Mannitol is a white, odorless, crystalline powder, or free-flowing 
granules. 
 It has a sweet taste. 
  Microscopically, it appears as orthorhombic needles when crystallized 
from alcohol. 
  Mannitol shows polymorphism. 
Pharmacopoeial Specifications: 
 Density (bulk):0.430 g/cm3. 
 Density (tapped):0.734 g/cm3. 
 Density (true): 1.514 g/cm3. 
 Dissociation constant: pKa = 13.5 at 188C. 
 Flowability: powder is cohesive, granules are free flowing. 
 Melting point: 166–168oC 
 Loss on drying:  40.3%  
Stability and Storage Conditions: 
It should be stored in a well-closed container in a cool, dry place. 
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Incompatibilities: 
 Mannitol solutions, 20% w/v or stronger, may be salted out by 
potassium chloride or sodium chloride. 
  Mannitol is incompatible with xylitol infusion and may form 
complexes with some metals such as aluminum, copper, and iron. 
  Reducing sugar impurities in mannitol have been implicated in the 
oxidative degradation of a peptide in a lyophilized formation.  
Handling Precautions: 
Mannitol may be irritant to the eyes; eye protection is recommended..  
(Hand book of Pharmaceutical excipients-5
th
 edition,449-453) 
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MICROCRYSTALLINE CELLULOSE 
Synonyms: 
 Avicel PH. 
 Celex. 
 Celphere. 
 Ceolus KG. 
 Ethispheres. 
 Fibrocel. 
 Pharmacel. 
 Tabulose. 
 Vivapur. 
Chemical Name: 
Cellulose. 
Empirical Formula: 
(C6H10O5) n 
Molecular Weight: 
36 000 
Functional Category: 
 Adsorbent. 
 Suspendingagent, Tablet and capsule diluents, tablet disintegrant. 
Application in Pharmaceutical Formulation: 
 Microcrystalline cellulose is used as a binder/diluent in oral tablet and 
capsule formulations.  
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 Microcrystalline cellulose is used as a lubricant and disintegrant agent in 
tablet formulation. 
 Microcrystalline cellulose is also used in cosmetics and food products.  
Description: 
Microcrystalline cellulose is a white, odorless, tasteless, crystalline powder 
composed of porous particles.  
Use Concentration (%) 
 Adsorbent: 20–90 
 Antiadherent: 5–20 
 Capsule binder/diluent: 20–90 
 Tablet disintegrant: 5–15 
 Tablet binder/diluents: 20–90 
Pharmacopoeial Specifications: 
 pH: 5.0–7.0  
 Loss on drying: 47.0%  
 Residue on ignition: 40.05% 
 Sulfated ash: 40.1% 
 Heavy metals: 410 ppm  
Typical Properties: 
 Density (tapped):0.478 g/cm3, 
 Density (true): 1.512–1.668 g/cm3 
 Flowability: 1.41 g/s for Emcocel 90M. 
 Melting point: chars at 260–2708C. 
 Microcrystalline cellulose is hygroscopic. 
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Stability and Storage Conditions: 
Microcrystalline cellulose is a stable though hygroscopic material. The bulk 
material should be stored in a well-closed container in a cool, dry place. 
Incompatibilities: 
Microcrystalline cellulose is incompatible with strong oxidizing agents. 
Handling Precautions: 
Microcrystalline cellulose may be irritant to the eyes. Gloves, eye protection, 
and a dust mask are recommended (Hand book of Pharmaceutical excipients-5
th
 
edition, 132-135). 
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TALC 
Synonyms: 
Altalc, E553b, hydrous magnesium calcium silicate, hydrous magnesium 
silicate, Luzenac Pharma, magnesium hydrogen metasilicate, MagsilOsmanthus, 
Magsil Star, powdered talc, purified French chalk, Purtalc, soapstone, steatite, 
Superiore. 
Chemical Name: 
Talc  
Empirical Formula: 
Mg6(Si2O5)4(OH)4. 
Chemical Structure: 
 
Functional Category: 
Anticaking agent, glidant, tablet and capsule diluent, tablet and capsule 
lubricant. 
Applications in Pharmaceutical Formulations: 
 Lubricant and diluents. 
 Dissolution retardant in the development of controlled-release products. 
 An adsorbant. 
 Dusting powder. 
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  Talc is additionally used to clarify liquids and is also used in cosmetics and 
food products, mainly for its lubricant properties. 
 Dusting powder: 90.0–99.0% 
 Glidant and tablet lubricant: 1.0–10.0% 
 Tablet and capsule diluents: 5.0–30.0% 
Description: 
Talc is a very fine, white to grayish-white, odorless, impalpable, unctuous, 
crystalline powder. It adheres readily to the skin and is soft to the touch and free 
from grittiness. 
Pharmacopoeial Specifications: 
 Acidity/alkalinity: pH = 7–10 for a 20% w/v aqueous dispersion. 
 Hardness (Mohs): 1.0–1.5 
 Solubility: practically insoluble in dilute acids and alkalis, organic solvents, 
and water. 
 Specific gravity: 2.7–2.8 
 Specific surface area: 2.41–2.42m2/g 
Stability and Storage Conditions: 
Talc is a stable material and may be sterilized by heating at 1608C for not 
less than 1 hour. It may also be sterilized by exposure to ethylene oxide or gamma 
irradiation.Talc should be stored in a well-closed container in a cool, dry place. 
Incompatibilities: 
Incompatible with quaternary ammonium compounds. 
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Handling Precautions: 
 Talc is irritant if inhaled and prolonged excessive exposure may cause 
pneumoconiosis. In the UK, the occupational exposure limit for talc is 1 mg/m3 of 
respirable dust long-term (8-hour TWA).Eye protection, gloves, and a respirator are 
recommended (Handbook ofPharmaceutical excipients- 5
th
 edition, 641-643). 
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PVP K 30  
SYNONYM 
 Kollidon  
 Plasdone 
 poly[1-(2-oxo-1-pyrrolidinyl)ethylene]   
 Polyvidone;Polyvinylpyrrolidone  
 PVP; 1-vinyl-2-pyrrolidinone polymer. 
STRUCTURE 
 
CHEMICAL NAME 
                       1-Ethenyl-2-pyrrolidinone homopolymer 
EMPIRICAL FORMULA 
            (C6H9NO)n               2500–3 000 000 
The USP 28 describes povidone as a synthetic polymer consisting essentially 
of linear 1-vinyl-2-pyrrolidinone groups, the differing degree of polymerization of 
which results in polymers of various molecular weights. It is characterized by its 
viscosity in aqueous solution, relative to that of water, expressed as a K-value, in the 
range 10–120.                                                                          
 The K-value is calculated using Fikentscher’s equation: 
                                                       log z =c      75k2 
                                                                         1+1.5kc     
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Where z is the relative viscosity of the solution of concentration c (in % w/v), 
and k is the K-value ×10
-3
 
MOLECULAR WEIGHT : 50000 
FUNCTIONAL CATEGORY: 
Disintegrant; dissolution aid; suspending agent; tablet binder 
DESCRIPTION: 
Povidone occurs as a fine, white to creamy-white colored, odorless or almost 
odorless, hygroscopic powder. 
PROPERTIES 
 Physical state  :      white powder 
Solubility                     :  freely soluble in acids, chloroform, ethanol (95%),                       
ketones,    methanol, and water; practically 
insoluble in ether, hydrocarbons, and mineral oil. 
HANDLING PRECAUTIONS: 
Observe normal precautions appropriate to the circumstances and quantity of 
material handled. Eye protection is recommended 
STABILITY AND STORAGE CONDITIONS: 
Povidone may be stored under ordinary conditions without undergoing 
decomposition or degradation. However, since the powder is hygroscopic, it should 
be stored in an airtight container in a cool, dry place. 
SAFETY: 
Povidone is widely used as an excipient, particularly in oral tablets and 
solutions. When consumed orally, povidone may be regarded as essentially nontoxic 
since it is not absorbed from the gastrointestinal tract or mucous membranes. 
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Additionally it has no irritant effect on the skin and causes no sensitization 
(Handbook of Pharmaceutical excipients- 5
th
 edition, 641-643). 
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CHAPTER IX 
EXPERIMENT PROTOCOL 
I. PREPARATION OF STANDARD CALIBRATION CURVE: 
a) Determination of λ max for ormeloxifene in distilled water and phosphate 
buffer pH (6.8): 
Ormeloxifene solution 10 µg/ml in distilled water and phosphate buffer pH 6.8 
solution is prepared then scanned by a UV spectrophotometer at wavelengths ranging 
from 400nm to 200nm, the λmax for solution was determined (Abd Al Hammid., et 
al, 2013). 
b) Calibration of ormeloxifene in distilled water and phosphate buffer pH (6.8): 
An accurately weighed quantity (100mg) of pure drug Ormeloxifene.Hcl is 
dissolved in sufficient amount of methanol and made up to 100ml with Distilled water 
to produce 1mg/ml solution. From this 10ml of the solution is pipette-out and made 
up to 100ml with distilled water. From this 5-25ml is pipette-out and diluted to 100ml 
with distilled water. The solution is scan within the range of 200nm-400nm in UV-
Spectrophotometer. The absorbance of the solutions is measured at 278nm by using 
UV spectrophotometer and distilled water was used as blank solution. The calibration 
graph is drawn by taking concentration in X-axis and respective absorbance in Y-axis 
to get a straight line as per Beers law. 
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c) Calibration of ormeloxifene with phosphate buffer pH 6.8 
    Preparation of pH 6.8 Phosphate Buffer Solution: 
50 ml of monobasic 0.2M Potassium phosphate solution in 200ml volumetric 
flask and added 22.4ml of 0.2 m sodium hydroxide then added water to make up the 
volume. 
    Preparation of 0.2 M Monobasic potassium phosphate solution  
Dissolved 27.22g of monobasic potassium phosphate in water and dilute with 
water to 1000ml. (Indian pharmacopeia 2010). 
An accurately weighed quantity (100mg) of pure drug Ormeloxifene.Hcl is 
dissolved in sufficient amount of methanol and made up to 100ml with pH 6.8 
phosphate buffer to produce 1mg/ml solution. From this 10ml of the solution is 
pipette-out and made up to 100ml with distilled water. From this 5-25ml is pipette-out 
and diluted to 100ml with distilled water. The solution is scan within the range of 
200-400 nm in UV-Spectrophotometer. The absorbance of the solutions is measured 
at 278nm by using UV spectrophotometer and phosphate buffer pH 6.8 was used as 
blank solution. The calibration graph is drawn by taking concentration in X-axis and 
respective absorbance in Y-axis to get a straight line as per Beers law (Abd Al 
Hammid., et al, 2013). 
II. COMPATIBILITY STUDIES FOR DRUG AND EXCIPIENTS: 
Compatibility studies are carried out to confirm there are no interactions existing 
between the drug and excipients. It gives information needed for selection of 
excipients with the drug for the formulation of solid dispersion. Infrared 
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spectrophotometry and Differential scanning calorimetry studies are the two 
techniques used to check the compatibility studies between drug and polymers. 
1) Differential Scanning Colorimetric(DSC) studies: 
The possibility of drug-polymer interaction was investigated by Differential 
scanning calorimetry (DSC 200 TA Instruments, USA). The DSC thermograms of 
pure drug and the polymers were recorded to study the interactions between drug and 
polymers. The samples were separately sealed in aluminium cells and set in a thermal 
analyzer. The thermal analysis was performed at a scanning rate of 10 
0
C per minute 
over a temperature range of 50-200 (Abdul Hasan Sathali A, and   Selvaraj V, 2012) 
2) Fourier Transform-Infra Red (FT-IR) Studies: 
 Ormeloxifene and β-cyclodextrin  are subjected to Fourier Transform Infra 
Red Spectroscopy studies (Shimadzu,Japan).Samples are prepared using KBr disc 
method and spectra are recorded over the range 600-4500 per cm. Spectra are 
analyzed for drug-carrier interaction and functional groups involved in the 
complexation process (Hyma P., et al, 2012). 
III. FORMULATION AND EVALUATION OF SOLID DISPERSIONS. 
a) Formulation and evaluation of solid dispersion  
Solid dispersion of Ormeloxifene hydrochloride is prepared by following 
methods 
i)   Kneading method 
ii)  Melting method 
iii) Co precipitation method 
iv) Solvent evaporation method 
v)   Physical mixture 
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i) Kneading method 
Ormeloxifene with β-cyclodextrin in the molar ratio of 1:1, 1:2, 1:3 and 1:4 
was taken in a clean glass mortar. First, β-cyclodextrin was placed in a mortar; a small 
quantity of 50% methanol was added to it while triturating to get slurry like 
consistency. Then the drug was slowly incorporated into the slurry and trituration was 
further continued for one hour. Slurry was then air dried at 25°C for 24 hours, 
pulverized, passed through sieve # 100 and stored in desiccators over fused silica gel 
(Prabhakar Shirse., et al., 2012). 
ii) Melting method
 
Water soluble carriers PEG 6000 are taken in a china dish and heated at 60ºC 
in a water bath, until the mixture melts completely. The drug (Ormeloxifene) is added 
to the molten polymer and mixed thoroughly. The dispersion is cooled to ambient 
condition. Solidified mass is crushed, pulverized and passed through sieve No. 120 
and stored in desiccators (Abdul Hasan Sathali.A and Selvaraj.V, 2012). 
iii) Co precipitation method
 
20%w/w  solution of ß-cyclodextrin(BCD)  was prepared at 75°C.An 
appropriate amount of the  drug  Ormeloxifene calculated according to the selected 
drug:BCD molar ratio (1:1, 1:2, 1:3, and 1:4) was then added to the solution, which 
was cooled to room  temperature while continuously stirring and shaking. During 
cooling, the solid drug ß-cyclodextrin complex precipitated (Deepthi Mathew et al., 
2009). 
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iv) Solvent evaporation method  
Ormeloxifene and the polymer [PEG – 6000] as per the ratio of 1:1, 1:2, 1:3, and 
1:4 were dissolved in a minimum amount of methanol. The solvent was removed by 
evaporation on magnetic stirrer at the temperature 40°C for 1hr. The resulting residue 
was dried for 2 hour and stored overnight in desicators. After drying, the residue was 
ground in a mortar and sieved through a mesh # 60. The resultant solid dispersions 
were stored in desiccators until further investigation (Abhilash M et al., 2013). 
v) Physical mixture 
Ormeloxifene  and ß-cyclodextrin (BCD) in 1:1, 1:2, 1:3 and 1:4  molar ratio 
were homogeneously blended in glass mortar for 1 hour and passed the blended  
through sieve no. 60, dried and finally stored in a desiccators (Shukla Vikesh et al., 
2009). 
b) Estimation of Percentage Yield  
Percentage yield is calculated to know about percent yield or efficiency of any 
method, thus it helps in selection of appropriate method of production.  Solid 
dispersions are collected and weighed to determined practical yield from the 
following formula (Kadam N.R., et al, 2010). 
        Practical mass (solid dispersion) 
Percentage Yield     =      ----------------------------------------        X 100 
                                              Theoretical mass (drug +carrier) 
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c) Determination of  Drug Content 
The physical mixtures and solid dispersions equivalent to 10mg of 
Ormeloxifene hydrochloride are weighed accurately and dissolved in 10ml of 
methanol. The solution is filtered, diluted suitably with distilled water and drug 
content is analyzed at λmax by UV –Spectrophotometer (Abdul Hasan Sathali.A and 
Selvaraj.V., et al, 2012). 
                                               Sample absorbance 
           %   Drug content =     ---------------------------------   X 100 
                                               Standard absorbance 
d) In vitro Dissolution Studies 
In vitro dissolution studies of Ormeloxifene hydrochloridel in pure drug form, 
physical mixtures and solid dispersions (SDs) are performed by using dissolution test 
apparatus (USP type II) at the paddle rotation speed of 50 rpm in 900ml of distilled 
water and temperature is maintained at 37°C± 0.5 °C. Samples equivalent to 10mg of 
Ormeloxifene hydrochloride is filled in hard gelatin capsules used for dissolution 
studies. Samples are collected at regular interval of time (10, 20, 30, 40, 50, 60 min). 
The absorbance of the samples is measured at λmax after suitable dilution using 
appropriate blank. The dissolution experiments are conducted in triplicate (Kadam 
N.R., et al, 2010). 
e) Selection of best formulation 
The selection of best formulation is done based on rate of ormeloxifene release 
by invitro dissolutio release studies. 
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IV. EVALUATION OF SELECTED FORMULATION 
a) Powder X Ray Diffraction Studies (PXRD) 
Powder X-ray diffraction patterns (XRD) of the pure drug, and solid 
dispersion (K 4) are recorded with an X-Ray Diffractometer (XD, Shimadzu, Japan) 
using copper as x-ray target, a voltage of 40 KV, a current of 30 mA and withn1.5404 
angestron wavelength..  The diffraction patterns run at 2.4 degree / min over the 2θ 
range of 2-50 degree. (Abdul Hasan Sathali.A and Selvaraj.V., 2012) 
b) Fourier Transform Infrared spectroscopic study.   
The possibility of drug-excipient interactions are further investigated by FT-
IR. The FT-IR graph of pure drug and combination of drug with excipient are 
recorded .The analysis is performed by using Shimadzu FT-IR Spectrometer. The 
scanning range was 450-4000 cm
-1 
and the resolution was 4cm
-1
. Samples were 
prepared in KBr pellets. (Kothawade.S.N., et al, 2010). 
c) Solubility Studies 
Solubility study is assessed out according to the method of Higuchi and 
Cannors. The solubility of racecadotril as pure drug, physical mixture and solid 
dispersion (K 4) are determined in distilled water and acid buffer PH 6.8. Samples are 
equivalent to 10mg of drug is taken and to this 10ml of respective medium is being 
added in 250ml conical flask, and shaken for 24 hours at room temperature on Rotary 
Flask Shaker. The entire samples are protected from light by wrapping the flask by 
aluminum foil. After 24 hours samples are filtered through whatman filter paper and 
aliquots are suitably diluted and assayed by spectrophotometrically at 278nm.(Abdul 
Hasan Sathali.A and Selvaraj.V.,2012) 
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V. PREFORMULATION STUDY FOR FAST DISSOLVING TABLETS 
1) Angle of Repose: 
           The friction forces in a loose powder can be measured by the angle of repose 
(θ). It is an indicative of the flow properties of the powder. 
It is defined as maximum angle possible between the surface of the pile of 
powder and the horizontal plane  
tan ( θ)   = tan-1  (h / r) 
Where,        
θ is the angle of repose.  
h is the height in cms 
r is the radius in cms.  
The powder mixture was allowed to flow through the funnel fixed to a stand at 
definite height (h). The angle of repose was then calculated by measuring the height 
and radius of the heap of powder formed. Care was taken to see that the powder 
particals slip and roll over each other through the sides of the funnel. Relationship 
between angle of repose and powder flow property (Debjit Bhowmik et al., 2009). 
2) Bulk Density: 
It is the ratio of total mass of powder to the bulk volume of powder. It was 
measured by pouring the weight powder (passed through standard sieve # 20) into a 
measuring cylinder and initial weight was noted. This initial volume is called the bulk 
volume. From this the bulk density is calculated according to the formula mentioned 
below. It is expressed in g/ml and is given by (Debjit Bhowmik et al ., 2009) 
Db   = M / Vb 
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  Where, M is the mass of powder, Vb is the bulk volume of the powder. 
3) Tapped Density: 
It is the ratio of total mass of the powder to the tapped volume of the powder. 
Volume was measured by tapping the powder for 750 times and the tapped volume 
was noted if the difference between these two volumes is less than 2%. If it is more 
than 2%, tapping is continued for 1250 times and tapped volume was noted. Tapping 
was continued until the difference between successive volumes is less than 2 % (in a 
bulk density apparatus). It is expressed in g/ml and is given by (Debjit Bhowmik et 
al., 2009) 
Dt =M / Vt 
Where,  
M is the mass of powder  
Vt is the tapped volume of the powder. 
 
4) Percentage of compressibility (or) Carr’s index: 
 It indicates powder flow properties. It is expressed in percentage and is give 
                      Dt - Db 
        I = ------------  ×100 
     Dt 
Where,  
Dt is the tapped density of the powder 
Db  is the bulk density of the powder. 
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Relationship between % compressibility and flowability 
% Compressibility Flow ability 
5 – 12 Excellent 
12 – 16 Good 
18 – 21 Fair Passable 
23 – 35 Poor 
33 – 38 Very Poor 
< 40 Very Very Poor 
  
5) Hausner ratio: 
Hausner ratio is an indirect index of ease of powder flow. It is calculated by 
the followingformula (Debjit Bhowmik et al., 2009). 
                               Dt 
Hausner ratio =      -------  
                                Db 
Where, 
Dt- is the tapped density. 
Db-is the bulk density.  
Lower hausner ratio (<1.25) indicates better flow properties than higher ones 
(>1.25). 
6) Precompression drug Content:    
10mg equivalent of Ormeloxefine drug complex was dissolved in sufficient 
amount of methanol and made upto 100ml of distilled water. From this solution 10ml 
was pipette out into 100ml volumetric standard flask and volume was made to 100ml 
with distilled water. The absorbance of the solution is measured at 278nm using 
CHAPTER- IX                                                               EXPERIMENTAL DETAILS 
 
Ormeloxifene FDT Reg. No: 261211307 Page 89 
 
distilled water as blank and the content of ormeloxefine is estimated.(Imran Shekh 
and et al, 2011) 
VI) FORMULATION OF ORMELOXIFENE FAST DISSOLVING TABLETS  
Fast dissolving/disintegrating tablets were prepared by using best resultant 
solid dispersion product K-4 [kneading mixture 1:4 molar ratio of Ormeloxifene HCl 
and ß- cyclodextrin]. The drug complex equivalent to 30 mg ormeloxifene   with 
variable concentration of superdisintegrants,  microcrystalline cellulose, 
talc,magnesium streate, pvp k-30  and mannitol ( for  cooling  effect and diluents)  in 
Powder blend equivalent to 250 mg of  average tablet weight.  
An accurately weighed quantity of kneading mixture (drug-carrier complex) is 
mixed with different ratio of superdisintegrant (Sodium starch glycolate, 
Crospovidone, CroscarmelloseSodium), microcrystalline cellulose and Mannitol, in 
geometrical dilution method. Then Magnesium stearate and Talc are added, mixed 
thoroughly and compressed into tablets by using single punching tablet machine to 
produce flat faced tablets. The average tablet weight is 250mg, with 8mm diameter. 
The compositions of the different formulations are given in Table (Sawarikar P.P et 
al., 2010). 
VII) POST COMPRESSION EVALUATION OF FAST DISSOLVING 
TABLET  
1) Thickness and diameter 
Tablet thickness and diameter can be measured using a simple procedure. 5 
tablets were taken and their thickness and diameter was measured using Varnier 
calipers (Amit Modi, 2012).         
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2)  Hardness 
It is the force required to break a tablet by compression in the radial direction, 
it is an important parameter in formulation of mouth dissolve tablets because 
excessive crushing strength significantly reduces the disintegration time (Debjit 
Bhowmik et al., 2009). 
3)  Weight variation test 
20 tablets were selected randomly from the lot and weighted individually to 
check for weight variation. Weight variation specification as per I.P. is shown in the 
table (Debjit Bhowmik et al., 2009). 
 
Average weight of tablet % Deviation 
80mg or Less ±10 
More than 80mg but less than 250mg ±7.5 
250mg or more ±5 
 
4) Friability test: 
Friability of the tablet determined using Roche friabilator. This device subjects 
the tablet to the combined effect of abrasion and shock in a plastic chamber revolving 
at 25 rpm and dropping a tablet at I height of 6 inches in each revolution. Preweighted 
sample of tablets was placed in the friabilator and were subjected to the 100 
revolutions. Tablets were dusted using a soft muslin cloth and reweighed. The 
friability (F) is given by the formula. (Debjit Bhowmik et al ., 2009) 
                                            W initial- W final 
                                F =     --------------------- × 100   
                                                        W initial           
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5) Uniformity of Drug Content:    
Twenty tablets of each type of formulation were weighed and crushed in 
mortar and powder equivalent to 10mg of Ormeloxefine was weighed and dissolved 
in methanol, the volume was made up to 100ml with pH 6.8 phosphate buffer. From 
the stock solution 1ml sample was withdrawn and diluted to 10ml with pH 6.8 
phosphate buffer, The absorbance was measured at wavelength 278nm using UV-
Visible spectrophotometer.Content uniformity was calculated using formula (Amit 
Modi, 2012). 
                                          Absorbance of unknown (Au) 
                   % Purity =     ------------------------------------------ X 10 C 
                                          Absorbance of Standard (As) 
Where,  
C – Concentration    
6) Invitro drug release studies: 
Dissolution studies of all tablets were performed using dissolution tester 
(Paddle type, LABINDIA 2000, India). Tablets were added to the 900 ml of 
Phosphate buffer pH 6.8 at 37°C ± 0.5°C, which was stirred with a rotating paddle at 
50 rpm.  5ml samples were withdrawn from the dissolution apparatus at the time in 
travel of 5, 10, 15, 20, 25, 30, 40, 50, and 60mins, equal volume of fresh medium was 
replaced in to the dissolution medium after each sampling to maintain its constant 
volume throughout the test. Assay carried out using UV spectrophotometer (Shimdzu 
1700 UV/Visible Spectrophotometer, Japan) at 278nm.(Indian pharmacopeia, 2010) 
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7) Solubility studies 
Solubility study is assessed out according to the method of Higuchi and 
Connors. The solubility of Ormeloxifene pure drug, kneading mixture and Fast 
dissolving tablets are determined in distilled water, phosphate buffer pH 6.8 and acid 
buffer pH 1.2. Samples equivalent to 10 mg of drug is taken and to this 10 mL of 
respective medium is being added in 250 mL conical flask, and shaken for 24 hours at 
room temperature on rotary flask shaker (Secor, India). The entire samples are 
protected from light by wrapping the flask by aluminum foil. After 24 hours samples 
are filtered through whatmann filter paper No. 42 and aliquots are suitably diluted and 
assayed by spectrophotometrically at 278 nm (Abdul Hasan Sathali A and Selvaraj V., 
2012). 
8) Disintegration time 
The test was carried out on 6 tablets using the apparatus specified in IP 2010 
distilled water at 37
o
C±2
o
C was used as a disintegration medium and the time in 
seconds taken for complete disintegration of the tablet with no palable mass 
remaining in the apparatus was measured in second (Shallesh Sharma et al., 2008) 
9) Water Absorption Ratio: 
A piece of tissue paper folded twice was placed in a small Petri dish 
containing 6 ml of water. A tablet was put on the paper & the time required for 
complete wetting was measured. The wetted tablet was then weighed. Water 
absorption ratio, R, was determined using following equation (Debjit Bhowmik et al., 
2009). 
R=10 (wa/wb) 
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where,   
Wb is weight of tablet before water absorption 
Wa is weight of tablet after water absorption. 
10) Wetting Time: 
Five circular tissue papers of 10 cm diameter are placed in a petridish with a 
10 cm diameter. Ten millimeters of water-containing Eosin, a water-soluble dye, is 
added to petridish. A tablet is carefully placed on the surface of the tissue paper. The 
time required for water to reach upper surface of the tablet is noted as a wetting time. 
(Debjit Bhowmik et al., 2009). 
VIII. BEST FORMULATION SELECTION 
Among twenty formulations, formulation the best was selected on the basis of 
lowest disintegration time and highest drug release profile, high water absorption 
ratio, low wetting time and minimum chemicals composition (Mangesh M.Kumare., 
et al, 2013). 
IX) STABILITY STUDY (Temperature Dependent) 
The fast dissolving tablet stored under following conditions for a period 
prescribed by ICH guidelines for accelerated studies. 40±1
0 
C, 50 ±1
0
C and 37±1
0
 C 
&RH 75 %± 5 %. The tablets  were withdrawn a period of 15 days and analyzed for 
physical characterization such as visual defects, hardness, Friability, disintegration 
and Dissolution etc. the data plotted into first order equations to determine the kinetics 
of degradation (Shallesh Sharma et al., 2008). 
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CHAPTER X 
RESULTS AND DISCUSSION 
1. PREPARATION OF STANDARD CALIBRATION CURVE 
a) Determination of λ-max for Ormeloxifene in Distilled water and phosphate 
buffer pH (6.8): 
The absorption maximum (max) of the ormeloxifene was estimated by 
scanning the drug solution (10µg/ml) between 200-400 nm regions on UV 
spectrophotometer. The obtained spectrum showed that the absorption maximum 
(max) was 278nm in distilled water and phosphate buffer pH 6.8, which was shown in 
Figure 1 (Anilkumar Shinde J et.al., 2010). 
b) Calibration of ormeloxifene hydrochloride in distilled water: 
 The Standard Calibration curves of ormeloxifene hydrochloride were prepared 
using distilled water.  The absorbances were measured at max of 278nm.  The 
correlation coefficient was found to be 0.9997. Ormeloxifene  hydrochloride 
obeys the beer’s law within the concentration range of (5-25µg/ml).  Calibration plot 
of ormeloxifene in distilled water was shown in Table 1(a) and Figure 2 (a). 
c) Calibration of ormeloxifene in phosphate buffer pH (6.8): 
The Standard Calibration curves of ormeloxifene hydrochloride were prepared 
using pH.6.8 phosphate buffer.  The absorbances were measured at max of 278nm.  
The correlation coefficient was found to be 0.9996. Ormeloxifene hydrochloride 
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obeys the beer’s law within the concentration range of (5-25µg/ml).  Calibration plot 
of ormeloxifene in ph 6.8 buffer was shown in Table 1 (b) and Figure 2(b). 
II. COMPATIBILITY STUDIES FOR DRUG AND EXCIPIENTS: 
1) Fourier Transform Infrared Spectroscopic studies: 
FT-IR spectrum of the pure drug, PEG 6000, Betacyclodextrin and physical 
mixtures was recorded.  Pure Ormeloxifene hydrochloride spectra showed sharp 
characteristic peaks at 2929.97, 1619.29, 1507.42, 1157.33, and 608.55 cm
-1
[Figure 
27 (a), 27 (e), 27 (h), 27 (n), 27 (q)]. All the above characteristic peaks appear in the 
IR spectrum of physical mixtures indicates that there is no modification or interaction 
between drug and carriers (Deshmukh D.B. et al., 2010).  
III. FORMULATION AND EVALUATION OF SOLID DISPERSIONS 
a)  Formulation of solid dispersions: 
In the present study, 16 formulations of ormeloxifene hydrochloride solid 
dispersions were prepared by using carriers like betacyclodextrin and  PEG6000 in the 
ratio of 1:1, 1:2, 1:3 and 1:4 in four methods (Kneading method, Melting method, Co 
precipitation method and Solvent evaporation method) (Table 2) .The prepared solid 
dispersions were found to be uniform and homogeneous in appearance. 
Betacyclodextrin carrier was used for kneading and co precipitation method of 
formulation, PEG6000 used in melting and solvent evaporation method formulations. 
b)  Estimation of Percentage Yield: 
The percentage yield of all the formulations was determined by weighing the 
practical yield. Percentage yield is calculated for all the formulations including 
physical mixture (Table 3). The percentage yield of solid dispersions ranged from 
83.6% - 96.88%.  The percentage yield of the solid dispersion M3 was found to be 
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high (96.88%) as compared to the other formulations.  Similarly the percentage yield 
of physical mixture ranged from 97.66 % - 98.39% which indicates that there is no 
considerable loss in the yield during the physical mixing process (Abhilash. M., et al. 
2013). 
c) Determination of Drug Content: 
The drug content in all the formulations was estimated spectrophotometrically 
at 278 nm (Shimadzu UV1700, Japan). The drug content of the prepared solid 
dispersions was found to be in the range of 84.39 % to 95.40% indicating the uniform 
distribution of drug in the formulation. (Table 4) (Abhilash. M., et al. 2013). 
d)  In vitro Dissolution Studies: 
The cumulative percentage drug release profile data obtained for all solid 
dispersion formulations and physical mixture are tabulated in Table no 5, 6, 7, 8 and 
9. The cumulative percentage of drug release of pure drug (Ormeloxifene 
hydrochloride) at the end of one hour was found to be 40.90% (Figure 3). 
In kneading method, betacyclodextrin was used as a carrier. The release 
profiles of formulation in the ratios of 1:1, 1:2, 1:3, and 1:4 were found to be 55.09% 
(K1), 68.59%(K2),  75.97%( K3), and 91.77 % ( K4) after 1 hour (Figure 4). From 
the results, it was observed that K4 (1:4 ratio) exhibits maximum drug release of 
91.77% and it was rated as the best formulation in kneading method using 
betacyclodextrin.   
In Melting method, PEG- 6000 was used as a carrier.  The release profile of 
PEG 6000 in the ratios of 1:1 ,1:2, 1:3,and 1:4  were found to be 42.18 % (M1),    
44.32 % (M2), 56.90 % (M3), and 63.45 % (M4) after 1 hour (Figure 5). From the 
results, it was observed that M4 (1:4 ratio) exhibits maximum release of 63.45 % and 
it was rated as the best formulation in melting method using PEG 6000. In 
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Coprecipitation method, betacyclodextrin was used as a carrier.  The release profile of  
BCD  in the ratios of 1:1 ,1:2, 1:3,and 1:4  were found to be 46.09 %(C1), 55.56 
%(C2), 66.66 %(C3),and 81.75 %(C4) after 1 hour(Figure 6). From the results, it was 
observed that C4 (1:4 ratio) exhibits maximum release of 81.75 % and it was rated as 
the best formulation in Co precipitation method using BCD. 
In Solvent evaporation method, PEG- 6000 was used as carrier. The release 
profiles of PEG - 6000 ,in the ratios  of 1:1, 1:2, 1:3,and  1:4 was found to be 
46.10%(S1), 49.67 %(S2),54.20%(S3),and 70.57 %(S4) after 1 hour (Figure 7). 
From the results it was observed that the release profile of K-4 (1:4 ratio) is 
higher than the release profiles of other formulations in this method. 
Comparision of methods 
 The invitro results indicated that the method of formulation influences the 
drug releases. Solid dispersion prepared with betacyclodextrin by kneading and co 
precipitation method. Kneading method, was found to be the best release rate of  
91.77 % (K-4) (Figure 8) at 1 hour, compared with the release profile of 
copercipitation method 81.75 %(C-4). The solid dispersion prepared by using PEG-
6000 by melting and solvent evaporation method, the solvent evaporation method was 
found to be the best with the release rate of 70.57 % (S-4) (Figure 9) at 1 hour, 
compared with the release profile of melting method 63.45 % (M-4). 
The physical mixture of drug with different carriers like betacylodextrin and 
PEG–6000 were prepared in 1:4 ratio was found to be the best release rate of 77 % by 
using betacyclodextrin (PB-4) (Figure 10) at 1 hour, compared with the release 
profile of PEG 6000 was 63.89 % (PP-4). 
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 The comparison of In-vitro drug release profile was shown in Figure 11. From 
the results it was observed that the release profile of K-4 prepared by kneading 
method was higher release profile than other formulations. So this was considered to 
be one of the best method for preparing ormeloxifene solid dispersion formulation. 
e) Selection of Best Formulation: 
The best formulation is selected based on the results obtained from the drug 
invitro release studies.  
Invitro dissolution studies revealed that there is marked increase in the 
dissolution rate of Ormeloxifene hydrochloride from all the solid dispersions when 
compared to physical mixture and pure drug.  
From the result it was observed that, between the two carriers, 
betacyclodextrin ratio was found to have greater release rate than other carrier used 
(Figure 12). The K-4 formulation (kneading method) containing drug and 
betacyclodextrin (1:4 ratio of drug: carrier) showed higher dissolution rate of 91.77% 
after 1hour, so it was considered as the overall best formulation (Figure 13).  
The order of drug release profile is  
Pure drug < Physical mixture < Solid dispersion 
The drug dissolution was increase in both, physical mixtures and solid 
dispersion product. It happens because of the enhanced wettability, hydrophilic nature 
of the carriers and possibility of reduced crystallinity of the drug and conversion of 
amorphous form of the drug. Solid dispersion product was homogeneously distributed 
within the carrier in an amorphous state and no drug crystallizes out of the dispersion, 
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suggesting that drug and polymer exist in the form of a mixture rather than the 
reaction product (Imran Shekh., etal, 2011).   
This study was planned to continue with best resultant product, various 
superdisintegrants and other excipients to formulate as fast dissolving tablets.  The 
formula as on Table No 11(a) and 11(b). 
IV.EVALUATION OF SELECTED FORMULATION: 
a) Powder X Ray Diffraction Studies (PXRD): 
 The XRPD patterns of pure drug (Ormeloxifene), excipients (BCD, Mannitol, 
MCC, PVP K30, CCS, CP and SSG), Kneading Mixture, and selected formulations 
(F8) were presented in (Figure 29a, 29b, 29c, 29d, 29e, 29f, 29g, 29h, 29i and 29j). 
 This result confirmed that the characteristic peaks were still preserved 
indicating the crystalline state was not changed. 
b) Fourier Transform Infrared spectroscopic study: 
IR Spectrum of the best formulation (K4- drug and betacyclodextrin 1:4 ratio 
of drug: carrier) was recorded. The pure Ormeloxifene spectra showed sharp 
characteristic peaks at 1613.29, 1455.34, 1368.54, 1157.33, 1029.06 and 480.29 cm
-
1
(Figure 27(u). All the above characteristic peaks appear in the IR spectrum of the 
best formulation which indicates that there was no interaction between drug and 
carriers.  
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c) Solubility Studies of Solid Dispersions: 
The solubility study was conducted with pure drug and selected best solid 
dispersion (K-4) product by distilled water and phosphate buffer pH 6.8 as shown in 
Table 10 and Figure 14.  It was observed that the solid dispersion product (K-4) 
showed high solubility in water (0.556mg/ml) and phosphate buffer pH 6.8 
(0.603mg/ml) as compared to pure drug solubility in water (0.266 mg/ml) and 
phosphate buffer pH 6.8  (0.3 mg/ml) (Nagesh C. et al., 2010). 
d) Differential Scanning Calorimetric (DSC) Studies: 
DSC thermogram of the best formulation was recorded. Pure Ormeloxifene 
exhibits a sharp endothermic peak at 144.95
0
C [Figure 28(a)]. An endothermic peak 
corresponding to the melting point of pure drug was prominent in best formulation 
(Kneading Mixture) [Figure 28(i)], which suggested clearly that there was no 
interaction between the drug and the polymers and the drug was existed in its 
unchanged form. 
V) PREFORMULATION STUDY FOR FAST DISSOLVING TABLETS: 
1) Angle of Repose: 
The angle of repose was used to determine the flow properties of powder 
blend. The angle of repose of all the formulations ranged from 20˚.88’ to 29˚.16’.The 
results indicated that all the formulations exhibited good flow properties. The results 
of angle of repose for all the formulations were shown in Table12 and Figure 15. 
2) Bulk density: 
The bulk density was used to determine the free flowing properties of powder 
blend.  The bulk density of all the formulations was in the range of 1.16 - 1.25g/cm
3.     
The values of bulk density showed that the blend was not tightly packed and indicated 
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good flow properties. The results of bulk density for all the formulations were shown 
in Table 12 and Figure 16. 
3) Tapped Density: 
The tapped density was used to access the free flowing properties of powder 
blend. The tapped density of all the formulations were in the range of 1.34-1.48 
g/cm
3
.The results indicated that the blends of all the formulation had good flow 
properties. The results of tapped density for all the formulations were shown in Table 
12 and Figure17. 
4) Carr’s Compressibility Index: 
The carr’s compressibility index was used to access the free flowing properties 
of powder blend. The compressibility index of all the formulations ranged from 11.34 
-15.8 %.This value below 16% indicates a powder having good flow property and 
good propensity of compression. The results of compressibility for all formulations 
were shown in Table 12and Figure18. 
5) Hausner’s Ratio: 
The Hausner’s ratio was an indirect index of ease of powder flow. The 
Hausner’s ratio of all the formulations ranged from 1.15-1.19. It was less than 1.25 
indicated better flow property of blend. The results of Hausner’s ratio for all the 
formulations were shown in Table 12and Figure19. 
6) Pre compression drug Content: 
The drug content of the tablets was used to ensure the therapeutic dosage of 
the active ingredient in the formulation. The drug content of all the formulation was in 
the range of 97.03 – 99.6 %.The results indicated all the formulations were within the 
acceptable limits as per USP. The results were shown in Table13. 
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7) Compatibility studies for drug and tablet excipients: 
i) Fourier Transform Infrared Spectroscopic studies: 
IR Spectrum of the best formulation (K4- drug and betacyclodextrin 1:4 ratio 
of drug: carrier), SSG, CCS, CP, PVP K30, MCC and physical mixtures was 
recorded. The pure Ormeloxifene spectra showed sharp characteristic peaks at 
2929.97, 1619.29, 1507.42, 1157.33, and 608.55 cm
-1 
[Figures 27(b), 27(c), 27(d), 
27(f), 27(g), 27(i), 27(j), 27(k), 27(l), 27(m), 27(o), 27(p), 27(r), 27(s), 27(t) and 
27(v)]. All the above characteristic peaks appear in the IR spectrum of the best 
formulation (K4) which indicates that there was no interaction between drug and 
carriers.  
VI) FORMULATION OF ORMELOXIFENE FAST DISSOLVING TABLETS: 
The fast dissolving tablet of ormeloxifene was prepared by direct compression 
method using resultant product of solid dispersion and different ratio (5%, 10%, and 
15%) of superdisintegrants (Sodium starch glycolate, Crospovidone and 
Croscarmellose sodium). The compositions of the different formulation were given in 
Table 11 (a) & 11(b). Twenty formulations (F1 to F20) were prepared as per formula 
designed. All the tablets were light white colour and round in shape having 8 mm 
diameter. 
VII)  POST COMPRESSION EVALUATION: 
The prepared tablets were evaluated on various parameters such as thickness 
and diameter, hardness, weight variation, friability, uniformity content, wetting time, 
water absorption ratio, In-vitro disintegration time and In-vitro dissolution test. The 
results were summarized in Table 13 & 14. 
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1) Thickness and Diameter: 
The thickness and diameter of all the formulations were used to determine the 
uniformity of size and shape of the tablets. From the results it was found that the 
thickness of the tablet in all formulation was 3.5- 3.7 mm and the diameter of the 
tablet in all formulation was 8mm.The results indicating all the formulations had 
uniform size and shape. The results were shown in Table 13. 
2) Hardness: 
The hardness of the tablets was used to determine the resistance capacity of 
the tablets to chipping, abrasion or breakage under conditions of storage, 
transportation and handling before usage. The hardness of the tablets of all the 
formulations was found to be 4kg/cm
2
.The result indicated that all the tablets had a 
good mechanical strength. The results   of the hardness for all the formulations were 
shown in Table 13. 
3) Weight Variation Test: 
The weight variation test was used to ensure the uniformity of the tablet in all 
formulations. The weight of all the tablets from each formulation was in the range 
from 245.7 mg to 248.76 mg. It was found all the tablets passed weight variation test, 
as the percentage weight variation was within the acceptable limits of 7.5%.The 
results were shown in Table 13. 
4) Friability test: 
Friability test was measured to ensure the mechanical strength of tablet. The 
results showed that the friability of all the formulation was ranged from 0.56 % to 
0.72%.Friability of all the formulation was lesser than 1 % which indicated the tablets 
had a good mechanical resistance. The results were shown in Table13. 
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5) Uniformity of drug Content: 
The uniformity content test was used to determine the uniform amount of 
active ingredient present in all formulations. The drug content in the content 
uniformity of all the formulations was found to be in the range of 97.06 % - 99.66 %. 
The results indicated all the formulations were within the acceptable limits as per USP 
limits. The results were shown in Table 13. 
6) In-vitro drug release Studies: 
The formulation dissolution profile range at 15minutes from 33.17 %  to 80.49 
% (table 14). The dissolution drug release rate was found to be comparatively less in 
formulation containing sodium starch glycolate. The maximum increased in the 
dissolution drug release rate was observed with the combination of crospovidone, 
croscarmellose sodium and sodium starch glycolate containing formulation (figure 20 
to 26). The order of the dissolution rate with various superdisintegrants was found to 
be 
Combination of disintegrants > crospovidone > croscarmellose sodium > SSG 
This study indicated that combination of superdisintegrants was produce better 
drug release rate than using alone. The formulation containing crospovidone, 
croscarmellose sodium and sodium starch glycolate was found to be showed 
dissolution after 15 minutes of dissolution study produce 80.49% which complies 
with WHO guild line (WHO Uganda., 2009). Many factors contributed for faster drug 
release rate such as rapid disintegration, smaller particle size, decrease in 
agglomeration of particles, increased wettability and decreased crystallinity of drug. 
Among the twenty formulations the formulation code (F-8) was selected, as a best 
formulation because of its desirable character of low disintegration time and highest 
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drug release, high water absorption rate, short wetting time and minimum chemicals 
composition.(Mangesh M.Kumare.,etal, 2013). 
7) Solubility studies: 
The solubility study was conducted with pure drug, solid dispersion product 
and best fast dissolving tablet (F-8) using distilled water and phosphate buffer pH 6.8 
as shown in Table 15 & Figure 14.  It was observed that the fast dissolving tablet F-8 
(0.79mg/ml) has highest solubility in water and phosphate buffer pH 6.8 (0.81 mg/ml) 
compared to pure drug in distilled water (0.26mg/ml) and phosphate buffer pH 6.8 
(0.3 mg/ ml).  
8) Disintegration Time: 
The in-vitro disintegration time was determined by disintegration test 
apparatus. The results were shown in Table 14. 
 Formulations F1, F2, F3, F4, F5, F6, F7, F8, F9, F10, F11, F12, F13, F14, 
F15, F16, F17, F18, F19 and F20  showed the  disintegration time 166, 145, 88, 129, 
86, 72, 155, 58, 70, 137, 148, 127, 123, 87, 86, 143, 126, 146, 129 and 87 seconds 
respectively. It was observed that Formulation F8 containing Crospovidone (5%), 
Croscarmellose sodium (5%) and Sodium starch glycolate (5%) containing tablet 
disintegrate rapidly in a short time (58 seconds).The results of disintegration of all the 
tablets were found to be lesser than 180 seconds. So all the formulation satisfied the 
criteria of fast dissolving tablets.  
In vitro disintegration study explained that there was decrease in disintegration 
time with successive addition of superdisintegrant concentration in formulation but 
comparatively co-processed formulations (combination of superdisintegrants) take 
least time for disintegration. Such a difference in disintegration time between all these 
formulations indicates that in co-processed formulation there might be increase in 
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capillary action of Superdisintegrants which might have led to improved water uptake. 
(Mangesh M.Kumare.,etal, 2013) 
9) Water Absorption Ratio: 
The water absorption ratio test was used to ensure the capacity of the 
superdisintegrant to absorb the water. The results of water absorption ratio of all the 
formulation were shown in Table 14.  
Formulations F1, F2, F3, F4, F5, F6, F7, F8, F9, F10, F11, F12, F13, F14, 
F15, F16, F17, F18, F19, and F20 showed the water absorption ratio  9.87%, 18.2%, 
45.25%, 21.08%, 40.37%, 57.61%, 13.34%, 73.75%, 71.59%, 12.57%, 20.80%, 
19.28%, 27.82%, 49.27%, 72.94%, 26.36%, 26.93, 22.68%, 32.09%, and 52%   The 
results showed that as concentration of superdisintegrant increased water absorption 
ratio was also increased. Formulation F8 containing combined superdisintegrants 
showed highest water absorption ratio (73.75%) than other formulation. 
The reason for high water absorption ratio for F-8 formulation, the combined 
superdisintegrant action of water wicking mechanism and capillary action into porous 
network of tablet, resulting rapidly absorbs water into its network than formulation 
prepared with other combination of superdisintegrants.(Mangesh M.Kumare.,etal, 
2013). 
10) Wetting Time: 
Wetting time of the tablet was used to assess the capacity of the tablets to 
disintegrate by swelling of water. All the formulations showed quick wetting, this 
may be due to ability of swelling and also capacity of absorption of water. The results 
of wetting time of all the formulations were shown in Table 14. 
The formulations  F1, F2, F3, F4, F5, F6, F7, F8, F9, F10, F11, F12, F13, F14, 
F15.F16, F17, F18, F19,and  F20showed the wetting time 228, 178, 116, 153, 126, 62, 
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181, 53, 59, 159, 162, 147, 141, 134, 120, 152, 131, 155, 126, and 99 seconds 
respectively. The results indicated that as the concentration of superdisintegrant and 
type of superdisintegrant influences wetting time. Formulation F8 containing 
crospovidone (5%), sodium starch glycolate (5%), and cross carmellose sodium (5%) 
shows lesser wetting time than other formulation. 
This may be due to fact that superdisintegrant perform their action of 
Crospovidone capillary action, Croscarmellose sodium wicking and swelling action 
and  Sodium starch glycolate disintegrate the tablet by swelling mechanism, on 
combine effect of these three leading to shorter wetting time. (Mangesh M.Kumare.,et 
al, 2013). 
VIII. BEST FORMULATION SELECTION: 
Among twenty formulations, the best was selected on the basis of lowest 
disintegration time, rapid drug release profile, higher water absorption ratio, short 
wetting time. Formulation F-8 showed lowest disintegration tine of 58 seconds, faster 
drug release rate of 80.49 in 15 minutes, 95.63% in 30 minutes, comparatively high 
water absorption ratio of 73.75%, short wetting time of 53 seconds and minimum 
chemicals composition. In those parameter would drive the F-8 formulation as a best 
comparatively.  
IX) STABILITY STUDY (Temperature Dependent): 
The stability studies of best formulation is carried out at an ambient 
temperature and relative humidity(40⁰C±2⁰C, RH75%±5%) for a period of 60 days to 
find out any physicochemical changes in the dispersions as per modified International 
Conference On Harmonization (ICH) guidelines.  Periodically samples are withdrawn 
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to estimate the drug content. The results are tabulated (Table-16) which indicates that 
there is no significant change in the drug content (Kavitha. R. et al., 2012). 
 
Table 1 (a): Calibration of Ormeloxifene.HCl with Distilled water 
 
S. No 
 
Concentration 
[ µg/ml ] 
Absorbance 
 
1 5 0.0426 ± 0.002 
2 10 0.0860 ± 0.001 
3 15 0.1276 ± 0.003 
4 20 0.1720 ± 0.002 
5 25 0.2180 ± 0.003 
                                                 = 0.9997 
 
Table 1(b): Calibration of Ormeloxifene.HCl with Phosphate buffer pH (6.8) 
 
 
 
 
 
 
 
 
                                                                                       = 0.9996 
 
S. No 
 
Concentration 
[ µg/ml ] 
Absorbance  
 
1 5 0.0446 ± 0.001 
2 10 0.0853 ± 0.003 
3 15 0.1353 ± 0.006 
4 20 0.1803 ± 0.002 
5 25 0.2260 ± 0.005 
Table 2: COMPOSITION OF SOLID DISPERSION 
 
 
 
S. No 
 
F. Code 
 
Method 
 
Ratio 
 
Composition 
 
1 K1 Kneading 1:1 Drug : BCD 
2 K2 Kneading  1:2 Drug : BCD 
3 K3 Kneading 1:3 Drug : BCD 
4 K4 Kneading 1:4 Drug : BCD 
5 M1 Melting 1:1 Drug : PEG 6000 
6 M2 Melting 1:2 Drug : PEG 6000 
7 M3 Melting 1:3 Drug : PEG 6000 
8 M4 Melting. 1:4 Drug : PEG 6000 
9 C1 Co precipitation 1:1 Drug : BCD 
10 C2 Co precipitation 1:2 Drug : BCD 
11 C3 Co precipitation 1:3 Drug : BCD 
12 C4 Co precipitation 1:4 Drug : BCD 
13 S1 Solvent evaporation 1:1 Drug : PEG 6000 
14 S2 Solvent evaporation 1:2 Drug : PEG 6000 
15 S3 Solvent evaporation 1:3 Drug : PEG 6000 
16 S4 Solvent evaporation 1:4 Drug : PEG 6000 
17 PB 3 Physical mixture 1:3 Drug : BCD 
18 PB 4 Physical mixture 1:4 Drug : BCD 
19 PP 3 Physical mixture 1:3 Drug : PEG 6000 
20 PP4 Physical mixture 1:4 Drug : PEG 6000 
Table 3: PERCENTAGE OF YIELD 
 
Sl.No 
 
F. Code 
 
 
Method 
 
 
Ratio 
 
 
% of yield 
 
1 K1 Kneading 1:1 83.60 ± 1.07 
2 K2 Kneading 1:2 88.33 ± 2.02 
3 K3 Kneading 1:3 85.19 ± 1.750 
4 K4 Kneading 1:4 96.60 ± 0.77 
5 M1 Melting 1:1 91.72 ± 1.79 
6 M2 Melting 1:2 95.35 ± 1.60 
7 M3 Melting 1:3 96.88 ± 0.31 
8 M4 Melting. 1:4 91.44 ± 1.81 
9 C1 Co precipitation 1:1 87.45 ± 2.09 
10 C2 Co precipitation 1:2 90.08 ± 0.61 
11 C3 Co precipitation 1:3 92.72 ± 1.93 
12 C4 Co precipitation 1:4 94.82 ± 1.02 
13 S1 Solvent evaporation 1:1 90.05± 1.58 
14 S2 Solvent evaporation 1:2 93.97± 1.68 
15 S3 Solvent evaporation 1:3 94.93 ± 1.40 
16 S4 Solvent evaporation 1:4 88.90 ± 0.56 
17 PB 3 Physical mixture 1:3 98.36 ± 0.35 
18 PB 4 Physical mixture 1:4 98.10 ± 0.44 
19 PP 3 Physical mixture 1:3 98.39 ± 0.31 
20 PP4 Physical mixture 1:4 97.66 ± 1.15 
Table 4: DRUG CONTENT OF SOLID DISPERSION PRODUCT 
 
 
Sl.No 
 
F. Code 
 
 
Method 
 
 
Ratio 
 
 
Drug content 
1 K1 Kneading 1:1 85.01 ± 2.94 
2 K2 Kneading 1:2 84.67 ± 1.89 
3 K3 Kneading 1:3 84.70 ± 1.39 
4 K4 Kneading 1:4 86.54 ± 4.61 
5 M1 Melting 1:1 93.26 ± 1.39 
6 M2 Melting 1:2 94.17 ± 0.52 
7 M3 Melting 1:3 95.40 ± 1.58 
8 M4 Melting. 1:4 86.04 ± 2.02 
9 C1 Co precipitation 1:1 86.3± 0.81 
10 C2 Co precipitation 1:2 84.39 ± 1.83 
11 C3 Co precipitation 1:3 88.37 ± 1.39 
12 C4 Co precipitation 1:4 88.75 ± 2.929 
13 S1 Solvent evaporation 1:1 85.08± 0.59 
14 S2 Solvent evaporation 1:2 86.30 ± 1.53 
15 S3 Solvent evaporation 1:3 91.74± 0.92 
16 S4 Solvent evaporation 1:4 85.65 ± 1.77 
17 PB 3 Physical mixture 1:3 93.02± 1.16 
18 PB 4 Physical mixture 1:4 94.95 ± 1.77 
19 PP 3 Physical mixture 1:3 92.02± 0.93 
20 PP4 Physical mixture 1:4 96.27 ± 0.40 
Table 5: CUMULATIVE % DRUG RELEASE OF ORMELOXIFENE.HCl 
USING BETACYCLODEXTRIN CARRIER BY KNEADING METHOD 
 
 
Table 6: CUMULATIVE % DRUG RELEASE OF ORMELOXIFENE.HCl 
 USING BETACYCLODEXTRINCARRIER BY COPRECIPITATION METHOD 
 
 
Time 
(min) 
 
 
Percentage of Drug release 
 
K1 
(1:1 ratio) 
 
 
K2 
(1:2 ratio) 
 
 
K3 
(1:3 ratio) 
 
 
K4 
(1:4 ratio) 
 
 
 
Pure Drug 
 
10 12.44 ± 2.59 19.67 ± 2.59 19.99 ± 2.07 18.29 ± 2.14 7.28 ± 1.18 
 
20 16.98 ± 3.10 25.28 ± 3.74 32.74 ± 2.04 40.73 ± 2.09 13.17 ± 1.57 
 
30 26.74 ± 3.60 33.33 ± 3.65 50.56 ± 4.66 62.64 ± 3.08 21.49 ± 0.61 
 
40 40.62 ± 1.59 57.95 ± 1.63 62.87 ± 4.55 79.49 ± 3.73 29.87 ± 1.18 
 
50 51.16 ± 3.95 64.45 ± 4.23 71.54 ± 2.83 87.17 ± 2.08 35.54 ± 1.59 
 
60 55.09 ± 4.91 68.59 ± 5.24 75.97 ± 3.77 91.77 ± 2.09 40.9 ± 1.60 
Time 
(min) 
 
 
Percentage of Drug release 
 
C1 
(1:1 ratio) 
 
 
C2 
(1:2 ratio) 
 
 
C3 
(1:3 ratio) 
 
 
 
C4 
(1:4 ratio) 
 
 
 
 
Pure Drug 
 
 
10 9.00 ± 1.57 14.16 ± 1.19 11.76 ± 2.06 30.33 ± 4.14 7.28 ± 1.18 
 
20 14.22 ± 1.58 21.45 ± 1.59 36.25 ± 4.87 46.99 ± 4.73 13.17 ± 1.57 
 
30 21.18 ± 1.80 29.84 ± 1.59 52.48 ± 8.09 57.57±5.418 21.49 ± 0.611 
 
40 28.52 ± 2.09 38.26 ± 3.17 59.79 ± 4.19 72.32±1.030 29.87 ± 1.18 
 
50 38.65 ± 1.59 47.41 ± 2.77 63.9 ± 3.70 77.21±3.596 35.54 ± 1.59 
 
60 46.09 ± 1.22 55.56 ± 2.69 66.66 ± 3.20 81.75 ± 2.64 40.9 ± 1.60 
 TABLE 7: CUMULATIVE % DRUG RELEASE OF ORMELOXIFENE.HCl 
  
 
USING PEG 6000 CARRIER BY MELTING METHOD 
 
TABLE 8: CUMULATIVE % DRUG RELEASE OF ORMELOXIFENE.HCl 
 USING PEG 6000 CARRIER BY SOLVENT EVAPORATION METHOD 
Time 
(min) 
 
 
Percentage of Drug release 
 
M1 
(1:1 ratio) 
 
 
M2 
(1:2 ratio) 
 
 
M3 
(1:3 ratio) 
 
 
M4 
(1:4 ratio) 
 
 
Pure Drug 
 
 
10 7.78 ± 2.86 10.71 ± 3.07 28.60 ± 2.15 23.84 ± 3.23 7.28 ± 1.18 
 
20 11.45 ± 3.63 15.24 ± 2.58 34.59 ± 2.03 34.44 ± 4.73 13.17 ± 1.57 
 
30 15.97 ± 4.79 22.55 ± 1.58 41.17 ± 2.04 41.96 ± 3.11 21.49 ± 0.61 
 
40 25.00 ± 3.24 29.57 ± 1.06 48.43 ± 1.04 48.73 ± 4.15 29.87 ± 1.18 
 
50 35.11 ± 1.62 33.5 ± 2.16 53.13 ± 1.54 56.91 ± 4.81 35.54 ± 1.59 
 
60 42.18 ± 3.63 44.32 ± 3.75 56.90 ± 1.57 63.45 ± 3.80 40.9 ± 1.60 
Time 
(min) 
 
 
Percentage of Drug release 
 
 
PB 3 
(1:3 ratio) 
 
 
PB 4 
(1:4 ratio) 
 
 
PP 3 
(1:3 ratio) 
 
 
PP 4 
(1:4 ratio) 
 
 
 
Pure Drug 
 
 
 
10 15.15 ± 3.16 20.31 ± 2.58 11.37 ± 1.60 13.78 ± 2.04 7.28 ± 1.18 
 
20 30.04 ± 3.33 32.14 ± 2.17 17.28 ± 1.20 21.76 ± 3.13 13.17 ± 1.57 
 
30 45.33 ± 1.58 50.20 ± 1.78 28.74 ± 1.60 32.23 ± 2.18 21.49 ± 0.61 
 
40 59.02 ± 1.23 62.18 ± 2.17 42.31 ± 2.59 42.00 ± 2.79 29.87 ± 1.18 
 
50 65.89 ± 2.67 69.41 ± 2.76 54.60 ± 4.75 53.61 ± 3.63 35.54 ± 1.59 
 
60 73.78 ± 1.02 77.00 ± 2.77 62.79 ± 3.71 63.89 ± 4.25 40.9 ± 1.60 
TABLE 9: CUMULATIVE % DRUG RELEASE OF ORMELOXIFENE.HCL 
USING CARRIER BCD AND PEG 6000 BY PHYSICAL MIXTURE 
 
 
TABLE 10: COMPARISION OF SOLUBILITY STUDY OF 
ORMELOXIFENE.HCl USING DISTILLED WATER AND BUFFER pH6.8 
 
Time 
(min) 
 
 
Percentage of Drug release 
 
S1 
(1:1 ratio) 
 
 
S2 
 (1:2 ratio) 
 
 
S3 
 (1:3 ratio) 
 
 
 
S4 
(1:4 ratio) 
 
 
 
Pure Drug 
 
 
 
10 8.33 ± 1.57 12.1 ± 1.57 14.13 ± 1.56 17.58 ± 2.58 7.28 ± 1.18 
 
20 14.52 ± 1.18 23.61 ± 7.46 22.46 ± 0.56 28.85 ± 0.68 13.17 ± 1.57 
 
30 22.87 ± 3.17 27.09 ± 1.17 32.56 ± 1.81 37.77 ± 2.09 21.49 ± 0.61 
 
40 31.61 ± 2.74 35.49 ± 3.11 40.28 ± 1.18 48.30 ± 2.73 29.87 ± 1.18 
 
50 42.06 ± 3.76 44.61 ± 1.18 48.09 ± 2.39 62.01 ± 2.08 35.54 ± 1.59 
 
60 46.10 ± 2.16 49.67 ± 2.07 54.20 ± 1.61 70.57 ± 2.02 40.9 ± 1.60 
S.NO Formulation 
Distilled water 
(mg/ml) 
BufferPh 6.8 
(mg/ml) 
1 PURE DRUG 0.266 ± 0.01 0.30 ± 0.01 
2 SOLID DISPERSION (K-4) 
(DRUG:BCD 1:4) 
0.556 ± 0.01 0.603 ± 0.01 
  TABLE 11(a): ORMELOXIFENE FAST DISSOLVING TABLET FORMULA [F1 – F10] 
 
 
 
Ingredients F 1 F 2 F 3 F 4 F 5 F 6 F 7 F 8 F 9 F 10 
Ormeloxifene Drug complex 
Equivalent to 30mg  150mg 150mg 150mg 150mg 150mg 150mg 150mg 150mg 150mg 150mg 
Microcrystalline cellulose - - - 25mg 25mg 25mg - - 25mg - 
Sodium starch glycolate 12.5 mg 25mg 37.5mg 12.5mg 25mg 37.5mg 12.5mg 12.5mg 12.5mg - 
Croscarmellose sodium - - - - - - 12.5mg 12.5mg 12.5mg 12.5mg 
Crospovidone - - - - - - - 12.5mg 12.5mg - 
Polyvinyl Pyrolidone K-30 7.5 mg 7.5 mg 7.5 mg 7.5 mg 7.5 mg 7.5 mg 7.5 mg 7.5 mg 7.5 mg 7.5 mg 
Magnesium stearate 2.5mg 
2.5mg 2.5mg 2.5mg 2.5mg 2.5mg 2.5mg 2.5mg 2.5mg 2.5mg 
Talc 2.5mg 
2.5mg 2.5mg 2.5mg 2.5mg 2.5mg 2.5mg 2.5mg 2.5mg 2.5mg 
Mannitol  (Q S up to 250mg ) 75mg 62.5mg 50mg 50mg 37.5mg 25mg 62.5mg 50mg 25mg 75mg 
TABLE 11(b): ORMELOXIFENE FAST DISSOLVING TABLET FORMULA [F11 – F20] 
 
 
 
Ingredients 
F 11 F 12 F 13 F 14 F 15 F 16 F 17 F 18 F 19 F 20 
Ormeloxifene Drug complex 
Equivalent to 30 mg 
150mg 150mg 150mg 150mg 150mg 150mg 150mg 150mg 150mg 150mg 
Microcrystalline cellulose 
- - 25mg 
 
25mg 
 
25mg 
 
25mg 
 
25mg - - - 
Sodium starch glycolate 
- - - - - 12.5mg - - - - 
Croscarmellose sodium 
25mg 37.5mg 12.5mg 25mg 37.5mg 12.5mg 12.5mg - - - 
Crospovidone 
- - - - - - 12.5mg 12.5mg 25mg 37.5mg 
Polyvinyl Pyrolidone K-30 
7.5 mg 
 
7.5 mg 
 
7.5 mg 
 
7.5 mg 
 
7.5 mg 
 
7.5 mg 
 
7.5 mg 
 
7.5 mg 
 
7.5 mg 
 
7.5 mg 
Magnesium stearate 
2.5mg 2.5mg 2.5mg 2.5mg 2.5mg 2.5mg 2.5mg 2.5mg 2.5mg 2.5mg 
Talc 
2.5mg 2.5mg 2.5mg 2.5mg 2.5mg 2.5mg 2.5mg 2.5mg 2.5mg 2.5mg 
Mannitol  (Q S up to 250 mg ) 
126mg 100mg 100mg 75mg 50mg 75mg 75mg 150mg 125mg 100mg 
 Table 12: PREFORMULATION STUDIES FOR FAST DISSOLVING TABLET 
FORMULATION 
F-Code 
 
Angle of repose 
 
Bulk 
Density 
 
Tapped 
Density 
 
% of 
Compressibility 
 
Hausner ratio 
 
F-1 24.54 ± 1.84 1.23 ± 0.02 1.45 ± 0.02 14.87 ± 2.85 1.174 ± 0.03 
F-2 25.68 ± 1.66 1.25 ±0 1.48 ± 0.02 17.51 ± 0.26 1.19 ± 0.02 
F-3 23.09 ± 0.22 1.19 ± 0.01 1.39 ± 0.02 14.08 ± 1.96 1.15 ± 0.03 
F-4 24.15 ± 2.30 1.22 ± 0.01 1.41 ± 0.02 13.02 ± 1.53 1.14 ± 0.02 
F-5 20.95 ± 0.94 1.17 ± 0.01 1.36 ± 0.01 13.96 ± 0.17 1.15 ± 0.05 
F-6 28.64 ± 0.43 1.23 ± 0.02 1.45 ± 0.02 14.9 ± 0.10 1.17 ±0 
F-7 29.85 ± 0.71 1.22 ± 0.01 1.38 ± 0.00 11.34 ± 1.66 1.12 ± 0.02 
F-8 20.95 ± 0.85 1.19 ± 0.01 1.39 ± 0.02 14.08 ± 1.96 1.16 ± 0.02 
F-9 22.55 ± 3.5 1.17 ± 0.01 1.34 ± 0.05 15.21 ± 1.25 1.17 ± 0.01 
F-10 29.16 ± 2.73 1.18 ± 0.01 1.36 ± 0.01 13.22 ± 1.20 1.14 ± 0.01 
F-11 23.14 ± 0.60 1.19 ± 0.01 1.40 ± 0.02 15.17 ± 1.67 1.17 ± 0.02 
F-12 21.64 ± 1.91 1.18 ± 0.01 1.37 ± 0.01 13.85 ± 2.046 1.15 ± 0.02 
F-13 20.88 ± 0.61 1.19 ± 0.01 1.40 ± 0.02 14.91 ± 1.22 1.17 ± 0.02 
F-14 22.63 ± 1.23 1.18 ± 0.01 1.39 ± 0.02 15.29 ± 1.33 1.17 ± 0.02 
F-15 22.39 ± 1.27 1.16 ±0 1.37 ± 0.01 15.31 ± 1.07 1.17 ± 0.01 
F-16 21.94 ± 0.53 1.18 ± 0.01 1.38 ±0.00 14.48 ± 1.25 1.16 ± 0.01 
F-17 21.25 ± 1.56 1.18 ± 0.01 1.37 ± 0.01 13.86 ± 0.17 1.15 ± 0.01 
F-18 23.78 ± 1.46 1.21 ± 0.03 1.40 ± 0.02 13.50 ± 1.42 1.15 ± 0.02 
F-19 21.70 ± 1.67 1.18 ± 0.01 1.40 ± 0.02 15.80 ± 0.14 1.18 ± 0.00 
F-20 22.39 ± 0.20 1.17 ± 0.01 1.38 ± 0.00 14.97 ± 1.10 1.17 ± 0.01 
 
Table 13: POST COMPRESSION EVALUATION STUDY FOR ORMELOXIFENE 
FAST DISSOLVING TABLET FORMULATIONS 
 
F-Code 
 
Weight 
uniformity 
test ± SD 
DC(mg) ± SD 
  
Hardness 
[kg/cm2] 
  
Thickness 
(mm) 
 
Friability 
[%] 
 
F -1 244.35 ± 3.34 29.73 ± 0.17 4 3.7 0.61 
F -2 243.62 ± 4.52 29.4 ± 0.45 4 3.6 0.7 
F -3 248.49 ± 3.30 29.41 ± 0.12 4 3.7 0.68 
F -4 248 ±4. 22 29.89 ± 0.82 4 3.7 0.69 
F -5 246.04 ±  3.73 29.20 ± 0.35 4 3.7 0.72 
F -6 248.11 ± 2.89 29.47± 0.30 4 3.7 0.67 
F -7 247.32 ± 1.9 29.32 ± 0.34 4 3.7 0.63 
F -8 248.76 ± 2.09 29.33 ± 0.34 4 3.7 0.71 
F -9 247.98 ± 2.39 29.39 ± 0.17 4 3.7 0.7 
F -10 247.6 ± 2.69 29.81 ± 0.47 4 3.7 0.56 
F -11 247.1 ± 1.73 29.47 ± 0.21 4 3.7 0.67 
F -12 146.35 ± 1.2 29.37 ± 0.34 4 3.5 0.66 
F -13 246.98 ± 1.38 29.40 ± 0.17 4 3.5 0.56 
F -14 248.3 ± 1.28 29.66 ± 0.43 4 3.5 0.7 
F -15 246.69 ± 1.42 29.19 ± 0.27 4 3.7 0.63 
F -16 246.93 ± 1.02 29.12 ± 0.11 4 3.6 0.69 
F -17 247.17 ± 1.28 29.10 ± 0.27 4 3.6 0.63 
F -18 247.14 ± 0.99 29.31 ± 0.34 4 3.7 0.69 
F -19 247.45 ± 0.95 29.37 ± 0.30 4 3.7 0.6 
F -20 245.7 ± 2.79 29.22 ± 0.34 4 3.7 0.69 
Table 14: POST COMPRESSION EVALUATION STUDY FOR ORMELOXIFENE 
FAST DISSOLVING TABLET FORMULATIONS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
F- code 
 
Disintegration 
Time [Sec] 
 
 
Water Ab. 
Ratio (%) 
 
Wetting 
Time [Sec] 
 
F -1 166.33 ±1.52 9.87 ±1.17 228.33 ±2.08 
F -2 145.66 ±2.08 18.20 ±1.33 178.33 ±1.52 
F -3 88.33 ±1.52 45.25 ±2.04 116.33 ±1.52 
F -4 129.66 ±2.08 21.08 ±1.72 153.33 ±2.51 
F -5 86.33 ±1.52 40.37 ±1.11 126.33 ±1.15 
F -6 72.33 ±2.08 57.61 ±1.34 62.66 ±1.52 
F -7 155.66 ±1.52 13.34 ±0.05 181.66 ±1.52 
F -8 58.33 ±1.52 73.75 ±2.27 53.66 ±1.52 
F -9 70.33 ±2.51 71.59 ±2.66 59.66 ±1.52 
F -10 137.66 ±1.52 12.57 ±1.34 159.66 ±1.52 
F -11 148.33 ±1.52 20.80 ±0.28 162.66 ±1.52 
F -12 127.66 ±1.52 19.28 ±0.76 147.66 ±1.52 
F -13 123.33 ±1.52 27.82 ±1.39 141.66 ±1.52 
F -14 87.66 ±1.52 49.27 ±0.42 134.66 ±0.57 
F -15 86.33 ±2.08 72.94 ±1.97 120.66 ±081 
F -16 143.66 ±1.52 26.36 ±0.23 152.33 ±1.15 
F -17 126.33 ±1.15 26.93 ±0.25 131.66 ±0.57 
F -18 146.33 ±2.08 22.68 ±0.38 155.66 ±1.52 
F -19 129.33 ±0.57 32.09 ±0.60 126.33 ±0.57 
F -20 87.33 ±2.081 52.00 ±0.13 99.33 ±2.30 
 Table 15: SOLUBILITY STUDY 
 
Medium 
Pure drug 
[mg/ml] 
Solid dispersion 
[mg/ml] 
Fast dissolving 
tablet [mg/ml] 
Distilled water 0.266 ± 0.01 0.556  ± 0.01 0.79  ± 0.01 
pH 6.8 buffer 0.3  ± 0.01 0.603  ± 0.01 0.81  ± 0.02 
 
 
Table 16: STABILITY STUDY 
 
 
Parameter Initial 
After 
10 days 
After 
20 days 
After 
30 days 
After 
45 days 
Physical appearance Pale white Pale white Pale white Pale white Pale white 
Hardness[kg/cm
2
] 4 4 4.5 4.5 4.8 
Water absorption ratio [%] 73.75 73.75 73.75 73.75 73.50 
Wetting time [ seconds] 53 53 56 56 58 
Disintegration time [Sec] 58 58 59 59 60 
Drug content [%] 97.76 97 97 96.33 96.33 
Drug release profile [%] 95 94.96 94.55 94.14 94.10 
FIGURE 1: DETERMINATION OF λ max OF ORMELOXIFENE 
HYDROCHLORIDE 
 
 
 
 
FIGURE 2(a): CALIBRATION OF ORMELOXIFENE HCL WITH 
DISTILLED WATER 
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FIGURE 2(b) CALIBRATION OF ORMELOXIFENE.HCL WITH pH 6.8 
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FIGURE 3: INVITRO RELEASE STUDY OF ORMELOXIFENE PURE DRUG 
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FIGURE 4: DISSOLUTION STUDY OF ORMELOXIFENE SOLID 
DISPERSION BY KNEADING METHOD 
 
 
FIGURE 5: DISSOLUTION STUDY OF ORMELOXIFENE SOLID 
DISPERSION BY MELTING METHOD 
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FIGURE 6: DISSOLUTION STUDY OF ORMELOXIFENE SOLID 
DISPERSION PRODUCT BY COPRECIPITATION METHOD 
 
 
FIGURE 7: DISSOLUTION STUDY OF ORMELOXIFENE SOLID 
DISPERSION PRODUCT BY SOLVENT EVAPORATION METHOD 
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FIGURE 8: COMPARISION OF INVITRO RELEASE PROFILE OF SOLID 
DISPERSION WITH DIFFERENT CARRIERS IN 1:1 RATIO 
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FIGURE 9: COMPARISION OF INVITRO RELEASE PROFILE OF SOLID 
DISPERSION WITH DIFFERENT CARRIERS IN 1:2 RATIO 
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FIGURE 10: COMPARISION OF INVITRO RELEASE PROFILE OF SOLID 
DISPERSION WITH DIFFERENT CARRIERS IN 1:3 RATIO 
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FIGURE: 11 COMPARISION OF INVITRO RELEASE PROFILE OF SOLID 
DISPERSION WITH DIFFERENT CARRIERS IN 1:4 RATIO 
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FIGURE 12: COMPARISION OF INVITRO RELEASE PROFILE OF 
PHYSICAL MIXTURE WITH DIFFERENT CARRIERS AND DIFFERENT  
RATIO 
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FIGURE 13: COMPARISION OF INVITRO RELEASE PROFILE OF BEST 
RELEASE SOLID DISPERSION IN  WITH DIFFERENT CARRIERS AND 
DIFFERENT  RATIO 
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FIGURE 14: SOLUBITY STUDY 
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FIGURE 15: ANGLE OF REPOSE 
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 FIGURE 16: BULK DENSITY 
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FIGURE 17: TAPPED DENSITY 
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FIGURE 18: CARR’S COMPRESSIBILITY 
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FIGURE 19: HAUSNER’S RATIO 
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 FIGURE 20: ORMELOXIFENE FAST DISSOLVING TABLET DRUG 
RELEASE PROFILE (F1 to F3) 
 
 
FIGURE 21: ORMELOXIFENE FAST DISSOLVING TABLET DRUG 
RELEASE PROFILE (F4 to F6) 
 
0 20 40 60
0
20
40
60
80
100
F-4
F-5
F -6
Time in Minutes
P
e
r
c
e
n
ta
g
e
 o
f 
d
r
u
g
 r
e
le
a
se
 
 
0 20 40 60
0
20
40
60
80
100
F-1
F-2
F -3
Time in Minutes
P
er
ce
n
ta
g
e 
o
f 
d
ru
g
 r
el
ea
se
 FIGURE 22: ORMELOXIFENE FAST DISSOLVING TABLET DRUG 
RELEASE PROFILE (F7 to F9) 
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FIGURE 23: ORMELOXIFENE FAST DISSOLVING TABLET DRUG 
RELEASE PROFILE (F10 to F12) 
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 FIGURE 24: ORMELOXIFENE FAST DISSOLVING TABLET DRUG 
RELEASE PROFILE (F13 to F15) 
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FIGURE 25: ORMELOXIFENE FAST DISSOLVING TABLET DRUG 
RELEASE PROFILE (F16 & F17) 
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FIGURE 26: ORMELOXIFENE FAST DISSOLVING TABLET DRUG 
RELEASE PROFILE (F18 to F20) 
 
0 20 40 60
0
20
40
60
80
100
F-18
F-19
F-20
Time in Minutes
P
e
r
c
e
n
ta
g
e
 o
f 
d
r
u
g
 r
e
le
a
se
 
 
 
 
 
 
 
 
 
 FIGURE 27 (a): FT-IR SPECTRUM OF ORMELOXIFENE 
 
 
 
FIGURE 27 (b): FT-IR SPECTRUM OF SODIUM STARCH GLYCOLATE 
 
 
 FIGURE 27 (c): FT-IR SPECTRUM OF CROSCARMELLOSE SODIUM 
 
 
FIGURE 27 (d): FT-IR SPECTRUM OF CROSPOVIDONE 
 
 FIGURE 27 (e): FT-IR SPECTRUM OF BETACYCLODEXTRIN 
 
 
 
 FIGURE 27 (f): FT-IR SPECTRUM OF MICROCRYSTALLINE 
CELLULOSE 
 
 FIGURE 27 (g): FT-IR SPECTRUM OF MANNITOL 
 
 
FIGURE 27 (h): FT-IR SPECTRUM OF PEG 6000 
 
 FIGURE 27 (i): FT-IR SPECTRUM OF PVP K30 
 
 
 
FIGURE 27 (j): FT-IR SPECTRUM OF (ORMELOXIFENE + CCS + CP+ 
MCC) 
 
 FIGURE 27 (k): FT-IR SPECTRUM OF (ORMELOXIFENE + SSG + CCS + 
CP+ MCC) 
 
 
FIGURE 27 (l): FT-IR SPECTRUM OF (ORMELOXIFENE + CCS + MCC)
 
 FIGURE 27 (m): FT-IR SPECTRUM OF (ORMELOXIFENE + SSG + CCS + 
MCC) 
 
 
FIGURE 27 (n): FT-IR SPECTRUM OF (ORMELOXIFENE + BCD) 
 
 FIGURE 27 (o): FT-IR SPECTRUM OF (ORMELOXIFENE + CCS) 
 
 
FIGURE 27 (p): FT-IR SPECTRUM OF (ORMELOXIFENE + CP) 
 
 FIGURE 27 (q): FT-IR SPECTRUM OF (ORMELOXIFENE + PEG 6000) 
 
 
FIGURE 27 (r): FT-IR SPECTRUM OF (ORMELOXIFENE + SSG + CCS) 
 
  
FIGURE 27 (s): FT-IR SPECTRUM OF (ORMELOXIFENE + SSG + MCC) 
 
FIGURE 27 (t): FT-IR SPECTRUM OF (ORMELOXIFENE + SSG) 
 
 
  
FIGURE 27 (u): FT-IR SPECTRUM OF KNEADING MIXTURE 
 
 
FIGURE 27 (v): FT-IR SPECTRUM OF FDT BEST FORMULATION (F8) 
 
  
 
 
 
 
 
 
 
FIGURE 28 (a): DSC THERMODRAM OF ORMELOXIFENE 
 
 
 
 
 
 
 
 
 FIGURE 28 (b): DSC THERMODRAM OF BETACYCLODEXTRIN 
 
 
 
FIGURE 28 (c): DSC THERMODRAM OF PEG 6000 
 
 
FIGURE 28 (d): DSC THERMODRAM OF CROSPOVIDONE 
 
 
 
FIGURE 28 (e): DSC THERMOGRAM OF SODIUM STARCH GLYCOLATE 
 
 
 
FIGURE 28 (f): DSC THERMOGRAM OF CROSCARMELLOSE SODIUM 
 
 
FIGURE 28 (g): DSC THERMODRAM OF MICROCRYSTALLINE 
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 FIGURE 28 (j): DSC THERMODRAM OF FDT BEST FORMULATION (F8) 
 
 
 
FIGURE 29 (a): XRD OF ORMELOXIFENE 
 
 
 FIGURE 29 (b): XRD OF BETACYCLODEXTRIN 
 
 
 
FIGURE 29 (c): XRD OF SODIUM STARCH GLYCOLATE 
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CHAPTER XI 
SUMMARY AND CONCLUSION 
 The purpose of this study was to prepare ormeloxifene fast dissolving tablets 
to improve the solubility and dissolution rate. 
 Ormeloxifene is very slightly soluble in water; so the study was plan to done 
in two steps. The first step was to improve solubility of ormeloxifene by solid 
dispersion, second step was to formulate fast dissolving tablet by using first 
step resultant product. 
 Kneading method, co precipitation, Melting Method and Solvent Evaporation 
Method were employed to prepare solid dispersions. 
 The formulated solid dispersions were characterized for in vitro release studies 
in distilled water, using USP Type II apparatus. 
 The solid dispersion systems of ormeloxifene hydrochloride prepared with the 
water soluble carriers betacyclodextrin and PEG 6000. Betacyclodextrin 
shows better invitro release. 
 The results revealed that the increase in the carrier concentration decreases the 
dissolution rate (1:4 ratios). 
 The invitro release studies revealed that the solid dispersion formulations 
showed a faster drug release when compared to the physical mixture and pure 
drug. 
 Infrared spectroscopic studies showed that there is no interaction between the 
drug Ormeloxifene hydrochloride and the carriers. 
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 The results of the Powder X-ray diffraction studies proved that crystallinity of 
the drug Ormeloxifene hydrochloride was considerably reduced in the best 
formulation (K4). 
 The solubility studies was observed that the solid dispersion (K- 4) have 
highest solubility compared to pure drug in distilled water and phosphate 
buffer pH 6.8. 
 The DSC thermogram of ormeloxifene hydrochloride reveal that the sharp 
melting point peak appeared at 140.12
0
C, whereas no such peak was observed 
in final product suggesting that Ormeloxifene hydrochloride was molecularly 
dispersed and in an amorphous form. 
 The solid dispersion is stable under normal storage condition. 
 The best resultant product was selected for fast dissolving formulation. The 
results of Differential Scanning calorimetry (DSC) and Fourier Transmission 
Infra-Red spectroscopy confirm that both drug (solid dispersion complex) and 
excipients are compatible with each other and are devoid of interactions. 
 The results of precompression studies like angle of repose, bulk density, 
tapped density, compressibility index and Hausner’s ratio reveals that the 
prepared powder blends of all formulations possess good flow properties. 
 The tablets were prepared by direct compression method using 
superdisintegrants like Croscarmellose, Sodium starch glycolate, 
Crospovidone, Microcrystalline cellulose in different concentrations of 5%, 10 
%, 15 %, PVP k-30 used as binder, and Mannitol is used as both sweetener 
and diluents, The tablets obtained were of uniform shape and size. 
 The prepared tablets were subjected to post compression evaluations and the 
results indicate that 
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 The hardness, thickness and diameters of all the tablets are uniform, which 
ensures that all the tablets were of uniform size and shape with good resistance 
against mechanical damage. 
 The tablets of all formulations contains uniform amount of drug, which 
ensures content uniformity for tablets of all formulations. 
 The tablets were within the limits of weight variation test, which in turn 
indicate uniform distribution of contents of the powder blends of each 
formulations. 
 The friability of all the tablets was found to be ˂  1%, which indicates the 
good mechanical resistance. 
 The tablets of all formulations were found to have minimum wetting time and 
maximum water absorption ratio which is the desired characteristic of fast 
dissolving tablets, which enables faster disintegration of tablets. 
 The disintegration time of all tablets were found to be less than three minutes, 
which ensures faster disintegration. 
 The tablets of all the formulations were found to release more than 80% in 15 
minutes, which is the desired quality of fast dissolving tablets that helps in 
faster absorption of the drug and quick onset of therapeutic effect except for 
formulations (F8). The dissolution pattern of various disintegrants used in the 
formulation was found to be in the order of combined super disintegrants 
Crospovidone > Croscarmellose sodium > Sodium starch glycolate. 
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CONCLUSION: 
It was concluded, that ormeloxifene hydrochloride can be successfully 
formulated as fast dissolving tablets using various superdisintegrants in different 
concentrations by direct compression method.The formulation containing 5% of 
crospovidone, 5% croscarmellose sodium and  5% sodium starch glycolate as 
superdisintegrant was found to be outstanding than other formulations in terms of 
disintegration time and rate of dissolution. 
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